Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24327537,flow rate,The mobile phase consisted of acetonitrile-water (containing 1 mmol/L ammonium formate) at gradient elution mode with a flow rate of 0.3 mL/min.,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),[ml] / [min],0.3,6304,DB02709,Resveratrol
,24327537,m/z,Oxyresveratrol and resveratrol were detected on MRM by the transitions from the precursor to the product ion (m/z 243.1 → 175.1 and 227.1 → 143.0).,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),,243.1,6305,DB02709,Resveratrol
,24327537,m/z,Oxyresveratrol and resveratrol were detected on MRM by the transitions from the precursor to the product ion (m/z 243.1 → 175.1 and 227.1 → 143.0).,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),,175.1,6306,DB02709,Resveratrol
,24327537,m/z,Oxyresveratrol and resveratrol were detected on MRM by the transitions from the precursor to the product ion (m/z 243.1 → 175.1 and 227.1 → 143.0).,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),,227.1,6307,DB02709,Resveratrol
,24327537,m/z,Oxyresveratrol and resveratrol were detected on MRM by the transitions from the precursor to the product ion (m/z 243.1 → 175.1 and 227.1 → 143.0).,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),,143.0,6308,DB02709,Resveratrol
,24327537,total running time,The total running time was 5 min and the retention times of oxyresveratrol and resveratrol were 1.97 and 1.82 min.,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),min,5,6309,DB02709,Resveratrol
,24327537,retention times,The total running time was 5 min and the retention times of oxyresveratrol and resveratrol were 1.97 and 1.82 min.,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),min,1.97,6310,DB02709,Resveratrol
,24327537,retention times,The total running time was 5 min and the retention times of oxyresveratrol and resveratrol were 1.97 and 1.82 min.,An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),min,1.82,6311,DB02709,Resveratrol
,24327537,extraction recovery,"The extraction recovery varied from 78.2 to 84.3% for low, medium and high quality control samples.",An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327537/),%,78.2 to 84.3,6312,DB02709,Resveratrol
,17548692,Peak plasma levels,"Peak plasma levels of resveratrol at the highest dose were 539 +/- 384 ng/mL (2.4 micromol/L, mean +/- SD; n = 10), which occurred 1.5 h post-dose.","Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17548692/),[ng] / [ml],539,6461,DB02709,Resveratrol
,17548692,Peak plasma levels,"Peak plasma levels of resveratrol at the highest dose were 539 +/- 384 ng/mL (2.4 micromol/L, mean +/- SD; n = 10), which occurred 1.5 h post-dose.","Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17548692/),[μM] / [l],2.4,6462,DB02709,Resveratrol
,26889234,Cmax,"Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively.",Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26889234/),[ng] / [ml],71.2,7569,DB02709,Resveratrol
,26889234,Cmax,"Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively.",Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26889234/),[ng] / [ml],"4,083.9",7570,DB02709,Resveratrol
,26889234,Cmax,"Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively.",Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26889234/),[ng] / [ml],"1,516.0",7571,DB02709,Resveratrol
,26889234,AUC0-inf,"Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively.",Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26889234/),[ng] / [ml],179.1,7572,DB02709,Resveratrol
,26889234,AUC0-inf,"Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively.",Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26889234/),[ng] / [ml],"39,732.4",7573,DB02709,Resveratrol
,26889234,AUC0-inf,"Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively.",Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26889234/),[ng] / [ml],"14,441.7",7574,DB02709,Resveratrol
,19194969,peak plasma concentration (C(max)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],3.89,11395,DB02709,Resveratrol
,19194969,peak plasma concentration (C(max)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],7.39,11396,DB02709,Resveratrol
,19194969,peak plasma concentration (C(max)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],23.1,11397,DB02709,Resveratrol
,19194969,peak plasma concentration (C(max)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],63.8,11398,DB02709,Resveratrol
,19194969,area under the plasma concentration-time curve (AUC(0-tau)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[h·ng] / [ml],3.1,11399,DB02709,Resveratrol
,19194969,area under the plasma concentration-time curve (AUC(0-tau)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[h·ng] / [ml],11.2,11400,DB02709,Resveratrol
,19194969,area under the plasma concentration-time curve (AUC(0-tau)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[h·ng] / [ml],33.0,11401,DB02709,Resveratrol
,19194969,area under the plasma concentration-time curve (AUC(0-tau)),"Following the 13th dose of trans-resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (C(max)) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration-time curve (AUC(0-tau)) was 3.1, 11.2, 33.0 and 78.9 ng.h/mL.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[h·ng] / [ml],78.9,11402,DB02709,Resveratrol
,19194969,half-life,Trans-resveratrol half-life was 1-3 h following single-doses and 2-5 h following repeated dosing.,Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),h,1-3,11403,DB02709,Resveratrol
,19194969,half-life,Trans-resveratrol half-life was 1-3 h following single-doses and 2-5 h following repeated dosing.,Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),h,2-5,11404,DB02709,Resveratrol
<,19194969,Trough (C(min)) concentrations,"Trough (C(min)) concentrations were < or = 1 ng/mL following 25 and 50 mg, 3 ng/mL following 100 mg and < 10 ng/mL following 150 mg.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],1,11405,DB02709,Resveratrol
,19194969,Trough (C(min)) concentrations,"Trough (C(min)) concentrations were < or = 1 ng/mL following 25 and 50 mg, 3 ng/mL following 100 mg and < 10 ng/mL following 150 mg.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],3,11406,DB02709,Resveratrol
<,19194969,Trough (C(min)) concentrations,"Trough (C(min)) concentrations were < or = 1 ng/mL following 25 and 50 mg, 3 ng/mL following 100 mg and < 10 ng/mL following 150 mg.",Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194969/),[ng] / [ml],10,11407,DB02709,Resveratrol
up to,26027429,oral bioavailability,The oral bioavailability of resveratrol when administered in these nanoparticles increased up to 50% (19.2-fold higher than for the control solution of the polyphenol).,Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26027429/),%,50,11837,DB02709,Resveratrol
,27983686,bioavailability,"Compared to capsule ingestion, consumption of polyphenol-rich beverages containing either dairy, soy or no proteins had minor to no effect on the bioavailability and excretion of phenolic compounds in plasma (118% ± 9%) and urine (98% ± 2%).","Impact of Proteins on the Uptake, Distribution, and Excretion of Phenolics in the Human Body. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27983686/),%,118,12400,DB02709,Resveratrol
,27983686,bioavailability,"Compared to capsule ingestion, consumption of polyphenol-rich beverages containing either dairy, soy or no proteins had minor to no effect on the bioavailability and excretion of phenolic compounds in plasma (118% ± 9%) and urine (98% ± 2%).","Impact of Proteins on the Uptake, Distribution, and Excretion of Phenolics in the Human Body. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27983686/),%,98,12401,DB02709,Resveratrol
,32952674,PDI,"The obtained RES-NCs displayed the particle size of 222.54 ± 1.66 nm, the PDI of 0.125 ± 0.035, the zeta potential of -9.41 ± 0.37 mV, and a rapid in vitro dissolution rate.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),,0.125,15517,DB02709,Resveratrol
,32952674,zeta potential,"The obtained RES-NCs displayed the particle size of 222.54 ± 1.66 nm, the PDI of 0.125 ± 0.035, the zeta potential of -9.41 ± 0.37 mV, and a rapid in vitro dissolution rate.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),mv,-,15518,DB02709,Resveratrol
,32952674,zeta potential,"The obtained RES-NCs displayed the particle size of 222.54 ± 1.66 nm, the PDI of 0.125 ± 0.035, the zeta potential of -9.41 ± 0.37 mV, and a rapid in vitro dissolution rate.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),mv,9.41,15519,DB02709,Resveratrol
,32952674,interaction energy,"Molecular dynamics simulation of RES and HPMC revealed an interaction energy of -68.09 kJ/mol and a binding energy of -30.98 ± 0.388 kJ/mol, indicating that the spontaneous binding between the two molecules is through van der Waals forces.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),[kj] / [mol],68.09,15520,DB02709,Resveratrol
,32952674,binding energy,"Molecular dynamics simulation of RES and HPMC revealed an interaction energy of -68.09 kJ/mol and a binding energy of -30.98 ± 0.388 kJ/mol, indicating that the spontaneous binding between the two molecules is through van der Waals forces.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),[kj] / [mol],30.98,15521,DB02709,Resveratrol
>,15907633,extraction efficiency,The mean extraction efficiency was >99%.,Determination and assay validation of pinosylvin in rat serum: application to drug metabolism and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907633/),%,99,17729,DB02709,Resveratrol
,15907633,limit of detection,The limit of detection was 100 ng/mL for a 0.1 mL sample.,Determination and assay validation of pinosylvin in rat serum: application to drug metabolism and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907633/),[ng] / [ml],100,17730,DB02709,Resveratrol
,12065739,elimination half-life (T(1/2),"After i.v. administration, plasma concentrations of RES(AGL) declined with a rapid elimination half-life (T(1/2), 0.13 h), followed by sudden increases in plasma concentrations 4 to 8 h after drug administration.","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),h,0.13,30531,DB02709,Resveratrol
,12065739,terminal elimination half-life,"These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of RES(AGL) (T(1/2TER), 1.31 h).","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),h,1.31,30532,DB02709,Resveratrol
,12065739,T(1/2TER),"These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of RES(AGL) (T(1/2TER), 1.31 h).","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),h,1.31,30533,DB02709,Resveratrol
,12065739,T(1/2TER),"RES(AGL) and RES(GLU) also displayed sudden increases in plasma concentrations 4 to 8 h after oral administration, with T(1/2TER) of 1.48 and 1.58 h, respectively.","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),h,1.48,30534,DB02709,Resveratrol
,12065739,T(1/2TER),"RES(AGL) and RES(GLU) also displayed sudden increases in plasma concentrations 4 to 8 h after oral administration, with T(1/2TER) of 1.48 and 1.58 h, respectively.","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),h,1.58,30535,DB02709,Resveratrol
,12065739,bioavailability,"RES(AGL) bioavailability was 38% and its exposure was approximately 46-fold lower than that of RES(GLU) (AUC(inf), 7.1 versus 324.7 micromol.h/l).","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),%,38,30536,DB02709,Resveratrol
,12065739,AUC(inf),"RES(AGL) bioavailability was 38% and its exposure was approximately 46-fold lower than that of RES(GLU) (AUC(inf), 7.1 versus 324.7 micromol.h/l).","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),[h·μM] / [l],7.1,30537,DB02709,Resveratrol
,12065739,AUC(inf),"RES(AGL) bioavailability was 38% and its exposure was approximately 46-fold lower than that of RES(GLU) (AUC(inf), 7.1 versus 324.7 micromol.h/l).","Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065739/),[h·μM] / [l],324.7,30538,DB02709,Resveratrol
,17097357,recovery,The average recovery of resveratrol from plasma and urine is 58+/-3%.,Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097357/),%,58,31001,DB02709,Resveratrol
,31353967,transmittance,"The optimum nano-emulsion consisted of Tween 20, Capryol 90, and Transcutol at a ratio of (54.26: 23.81: 21.93%v/v), and it exhibited transmittance of 100%, resveratrol solubility of 159.9 ± 6.4 mg/mL, globule size of 30.65 nm.","Nanosized nasal emulgel of resveratrol: preparation, optimization, in vitro evaluation and in vivo pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353967/),%,100,35949,DB02709,Resveratrol
,31353967,solubility,"The optimum nano-emulsion consisted of Tween 20, Capryol 90, and Transcutol at a ratio of (54.26: 23.81: 21.93%v/v), and it exhibited transmittance of 100%, resveratrol solubility of 159.9 ± 6.4 mg/mL, globule size of 30.65 nm.","Nanosized nasal emulgel of resveratrol: preparation, optimization, in vitro evaluation and in vivo pharmacokinetic study. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353967/),[mg] / [ml],159.9,35950,DB02709,Resveratrol
,31353967,globule size,"The optimum nano-emulsion consisted of Tween 20, Capryol 90, and Transcutol at a ratio of (54.26: 23.81: 21.93%v/v), and it exhibited transmittance of 100%, resveratrol solubility of 159.9 ± 6.4 mg/mL, globule size of 30.65 nm.","Nanosized nasal emulgel of resveratrol: preparation, optimization, in vitro evaluation and in vivo pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353967/),nm,30.65,35951,DB02709,Resveratrol
up to,31353967,Tmax,"Similarly, Tmax was increased up to 3.67 ± 0.82 h.","Nanosized nasal emulgel of resveratrol: preparation, optimization, in vitro evaluation and in vivo pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353967/),h,3.67,35952,DB02709,Resveratrol
,26792979,Self-em,Self-emulsification time averaged 17-99 seconds without precipitation and the mean droplet sizes ranged from 285 to 823 nm with overall zeta potential of -2.24 to -15.4 mv.,Self-emulsifying drug delivery systems as a tool to improve solubility and bioavailability of resveratrol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26792979/),seconds,17-99,36062,DB02709,Resveratrol
,26792979,overall zeta potential,Self-emulsification time averaged 17-99 seconds without precipitation and the mean droplet sizes ranged from 285 to 823 nm with overall zeta potential of -2.24 to -15.4 mv.,Self-emulsifying drug delivery systems as a tool to improve solubility and bioavailability of resveratrol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26792979/),mv,2.24,36063,DB02709,Resveratrol
,26792979,overall zeta potential,Self-emulsification time averaged 17-99 seconds without precipitation and the mean droplet sizes ranged from 285 to 823 nm with overall zeta potential of -2.24 to -15.4 mv.,Self-emulsifying drug delivery systems as a tool to improve solubility and bioavailability of resveratrol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26792979/),mv,15,36064,DB02709,Resveratrol
up to,33667833,recovery,The optimized extraction allowed to obtain analytes recovery up to 98.48 ± 4.03 %.,Development of an UHPLC-diode arrays detector (DAD) method for the analysis of polydatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33667833/),%,98.48,36981,DB02709,Resveratrol
,33667833,flow rate,"Chromatographic analysis was performed on a C18, 10 cm x 3.0 mm, 2.7 μm stationary phase, by using triethanolamine phosphate solution (0.1 M, pH = 3.7) and ACN 85:15 (v/v) as mobile phase at a flow rate of 0.5 mL/min.",Development of an UHPLC-diode arrays detector (DAD) method for the analysis of polydatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33667833/),[ml] / [min],0.5,36982,DB02709,Resveratrol
,33667833,limit of detection (LoD),The limit of detection (LoD) and the limit of quantification (LoQ) for polydatin in plasma samples were found to be 7.82 ± 0.38 nM and 26.06 ± 1.28 nM respectively.,Development of an UHPLC-diode arrays detector (DAD) method for the analysis of polydatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33667833/),nM,7.82,36983,DB02709,Resveratrol
,33667833,limit of quantification (LoQ),The limit of detection (LoD) and the limit of quantification (LoQ) for polydatin in plasma samples were found to be 7.82 ± 0.38 nM and 26.06 ± 1.28 nM respectively.,Development of an UHPLC-diode arrays detector (DAD) method for the analysis of polydatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33667833/),nM,26.06,36984,DB02709,Resveratrol
no less,19203616,extraction recovery,The extraction recovery from plasma was no less than 80%.,High-throughput quantification of a novel thiazolidinedione MCC-555 in rat plasma by ultra-fast liquid chromatography and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203616/),%,80,45087,DB02709,Resveratrol
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,0.027,53866,DB02709,Resveratrol
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,1,53867,DB02709,Resveratrol
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],57.8,53868,DB02709,Resveratrol
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],"19,200",53869,DB02709,Resveratrol
,19000554,maximum plasma concentration (Cmax),Mean +/- SD maximum plasma concentration (Cmax) was 42.2 +/- 36.6 ng/ml in fed and 47.3 +/- 30.0 ng/ml in fasting conditions.,Effect of food on the pharmacokinetic profile of trans-resveratrol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000554/),[ng] / [ml],42.2,54814,DB02709,Resveratrol
,19000554,maximum plasma concentration (Cmax),Mean +/- SD maximum plasma concentration (Cmax) was 42.2 +/- 36.6 ng/ml in fed and 47.3 +/- 30.0 ng/ml in fasting conditions.,Effect of food on the pharmacokinetic profile of trans-resveratrol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000554/),[ng] / [ml],47.3,54815,DB02709,Resveratrol
,19000554,time to Cmax (tmax),Median time to Cmax (tmax) was 2.0 h in fed and 0.5 h in fasting (p < 0.0001).,Effect of food on the pharmacokinetic profile of trans-resveratrol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000554/),h,2.0,54816,DB02709,Resveratrol
,19000554,time to Cmax (tmax),Median time to Cmax (tmax) was 2.0 h in fed and 0.5 h in fasting (p < 0.0001).,Effect of food on the pharmacokinetic profile of trans-resveratrol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000554/),h,0.5,54817,DB02709,Resveratrol
,25998136,apparent volume of distribution of the central compartment (V(c),"Following intravenous injection (4 mg/kg), DHS had a moderate apparent volume of distribution of the central compartment (V(c) = 887 ± 297 mL/kg), clearance (Cl = 44.7 ± 5.1 mL/min/kg) and a relatively short mean transit time (MTT = 24.1 ± 8.8 min).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),[ml] / [kg],887,55935,DB02709,Resveratrol
,25998136,clearance (Cl,"Following intravenous injection (4 mg/kg), DHS had a moderate apparent volume of distribution of the central compartment (V(c) = 887 ± 297 mL/kg), clearance (Cl = 44.7 ± 5.1 mL/min/kg) and a relatively short mean transit time (MTT = 24.1 ± 8.8 min).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),[ml] / [kg·min],44.7,55936,DB02709,Resveratrol
,25998136,mean transit time (MTT,"Following intravenous injection (4 mg/kg), DHS had a moderate apparent volume of distribution of the central compartment (V(c) = 887 ± 297 mL/kg), clearance (Cl = 44.7 ± 5.1 mL/min/kg) and a relatively short mean transit time (MTT = 24.1 ± 8.8 min).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),min,24.1,55937,DB02709,Resveratrol
,25998136,t max,"When it was given as an oral suspension (10 mg/kg), DHS was absorbed slowly (t max 180 or 300 min) with very limited plasma exposure and absolute oral bioavailability (F = 2.22 ± 0.72%).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),min,180,55938,DB02709,Resveratrol
,25998136,t max,"When it was given as an oral suspension (10 mg/kg), DHS was absorbed slowly (t max 180 or 300 min) with very limited plasma exposure and absolute oral bioavailability (F = 2.22 ± 0.72%).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),min,300,55939,DB02709,Resveratrol
,25998136,absolute oral bioavailability (F,"When it was given as an oral suspension (10 mg/kg), DHS was absorbed slowly (t max 180 or 300 min) with very limited plasma exposure and absolute oral bioavailability (F = 2.22 ± 0.72%).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),%,2.22,55940,DB02709,Resveratrol
,25998136,t(max),"On the other hand, when DHS was fully solubilized by hydroxypropyl-β-cyclodextrin, it was absorbed rapidly (t(max) 30 or 45 min) with more than 15-fold increase in maximal plasma concentration (C(max)), plasma exposure (AUC(0→last)) and bioavailability (F = 36.3 ± 4.8%).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),min,30,55941,DB02709,Resveratrol
,25998136,t(max),"On the other hand, when DHS was fully solubilized by hydroxypropyl-β-cyclodextrin, it was absorbed rapidly (t(max) 30 or 45 min) with more than 15-fold increase in maximal plasma concentration (C(max)), plasma exposure (AUC(0→last)) and bioavailability (F = 36.3 ± 4.8%).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),min,45,55942,DB02709,Resveratrol
,25998136,bio,"On the other hand, when DHS was fully solubilized by hydroxypropyl-β-cyclodextrin, it was absorbed rapidly (t(max) 30 or 45 min) with more than 15-fold increase in maximal plasma concentration (C(max)), plasma exposure (AUC(0→last)) and bioavailability (F = 36.3 ± 4.8%).","Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998136/),%,36.3,55943,DB02709,Resveratrol
,25137036,AUC,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),[pM] / [l],"48,418",56581,DB02709,Resveratrol
,25137036,AUC,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),[pM] / [l],"26,473",56582,DB02709,Resveratrol
,25137036,insulinogenic index,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),,0.48,56583,DB02709,Resveratrol
,25137036,insulinogenic index,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),,0.28,56584,DB02709,Resveratrol
,19444794,flow rate,The analytes were separated on a reversed-phase column with acetonitrile (40%) and water (60%) containing 0.75% formic acid as mobile phase at a flow rate of 1 mL/min.,"Liquid chromatography mass spectrometry for the determination of salvianolic acid B, a natural compound from the herb Danshen in rat plasma and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19444794/),[ml] / [min],1,56830,DB02709,Resveratrol
,24661109,bioavailability,"The drug suffers enterohepatic recirculation and extensive first-pass metabolism by CYP3A4 in liver, resulting in very low bioavailability (almost zero).",Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24661109/),,zero,60460,DB02709,Resveratrol
,27280934,IC50,"In addition, the formulation containing curcumin and resveratrol showed greater antioxidant activity than that of the formulations with individual compounds, while the cytotoxic activity against HT-29 of the co-formulation (IC50 = 18.25 µM; curcumin and resveratrol in the ratio 1 : 1) was less than the formulation with only curcumin (IC50 = 30.1 µM) and only resveratrol (IC50 = 25.4 µM).",A Novel Self-Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27280934/),μM,18.25,67604,DB02709,Resveratrol
,27280934,IC50,"In addition, the formulation containing curcumin and resveratrol showed greater antioxidant activity than that of the formulations with individual compounds, while the cytotoxic activity against HT-29 of the co-formulation (IC50 = 18.25 µM; curcumin and resveratrol in the ratio 1 : 1) was less than the formulation with only curcumin (IC50 = 30.1 µM) and only resveratrol (IC50 = 25.4 µM).",A Novel Self-Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27280934/),μM,30.1,67605,DB02709,Resveratrol
,27280934,IC50,"In addition, the formulation containing curcumin and resveratrol showed greater antioxidant activity than that of the formulations with individual compounds, while the cytotoxic activity against HT-29 of the co-formulation (IC50 = 18.25 µM; curcumin and resveratrol in the ratio 1 : 1) was less than the formulation with only curcumin (IC50 = 30.1 µM) and only resveratrol (IC50 = 25.4 µM).",A Novel Self-Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27280934/),μM,25.4,67606,DB02709,Resveratrol
,28475242,AUC0-t,"The systemic exposures to Res conjugates were much higher than those to Res (AUC0-t , i.v., 7.43 μm h; p.o., 8.31 μm h); Res-3-O-β-d-glucuronide was the major metabolite (AUC0-t , i.v., 66.1 μm h; p.o., 333.4 μm h).",A simple LC-MS/MS method facilitated by salting-out assisted liquid-liquid extraction to simultaneously determine trans-resveratrol and its glucuronide and sulfate conjugates in rat plasma and its application to pharmacokinetic assay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28475242/),h·μm,7.43,68827,DB02709,Resveratrol
,28475242,AUC0-t,"The systemic exposures to Res conjugates were much higher than those to Res (AUC0-t , i.v., 7.43 μm h; p.o., 8.31 μm h); Res-3-O-β-d-glucuronide was the major metabolite (AUC0-t , i.v., 66.1 μm h; p.o., 333.4 μm h).",A simple LC-MS/MS method facilitated by salting-out assisted liquid-liquid extraction to simultaneously determine trans-resveratrol and its glucuronide and sulfate conjugates in rat plasma and its application to pharmacokinetic assay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28475242/),h·μm,8.31,68828,DB02709,Resveratrol
,28475242,AUC0-t,"The systemic exposures to Res conjugates were much higher than those to Res (AUC0-t , i.v., 7.43 μm h; p.o., 8.31 μm h); Res-3-O-β-d-glucuronide was the major metabolite (AUC0-t , i.v., 66.1 μm h; p.o., 333.4 μm h).",A simple LC-MS/MS method facilitated by salting-out assisted liquid-liquid extraction to simultaneously determine trans-resveratrol and its glucuronide and sulfate conjugates in rat plasma and its application to pharmacokinetic assay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28475242/),h·μm,66.1,68829,DB02709,Resveratrol
,28475242,AUC0-t,"The systemic exposures to Res conjugates were much higher than those to Res (AUC0-t , i.v., 7.43 μm h; p.o., 8.31 μm h); Res-3-O-β-d-glucuronide was the major metabolite (AUC0-t , i.v., 66.1 μm h; p.o., 333.4 μm h).",A simple LC-MS/MS method facilitated by salting-out assisted liquid-liquid extraction to simultaneously determine trans-resveratrol and its glucuronide and sulfate conjugates in rat plasma and its application to pharmacokinetic assay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28475242/),h·μm,333.4,68830,DB02709,Resveratrol
,28475242,bioavailability,The bioavailability of Res was estimated to be ~22.4%.,A simple LC-MS/MS method facilitated by salting-out assisted liquid-liquid extraction to simultaneously determine trans-resveratrol and its glucuronide and sulfate conjugates in rat plasma and its application to pharmacokinetic assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28475242/),%,22.4,68831,DB02709,Resveratrol
,23351959,total recoveries,"Whether we administrated to rats of equimolar TARES or RES, total recoveries of RES in urine and feces within 36 h were low (0.99% or 0.07% in urine and 1.69% or 0.15% in feces).","Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351959/),%,0.99,71761,DB02709,Resveratrol
,23351959,total recoveries,"Whether we administrated to rats of equimolar TARES or RES, total recoveries of RES in urine and feces within 36 h were low (0.99% or 0.07% in urine and 1.69% or 0.15% in feces).","Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351959/),%,0.07,71762,DB02709,Resveratrol
,23351959,total recoveries,"Whether we administrated to rats of equimolar TARES or RES, total recoveries of RES in urine and feces within 36 h were low (0.99% or 0.07% in urine and 1.69% or 0.15% in feces).","Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351959/),%,1.69,71763,DB02709,Resveratrol
,23351959,total recoveries,"Whether we administrated to rats of equimolar TARES or RES, total recoveries of RES in urine and feces within 36 h were low (0.99% or 0.07% in urine and 1.69% or 0.15% in feces).","Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351959/),%,0.15,71764,DB02709,Resveratrol
,29534330,oral bioavailability,"However, the oral bioavailability of these compounds in humans is low (˂1-2%).",The Oral Bioavailability of Trans-Resveratrol from a Grapevine-Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534330/),%,˂1-2,73850,DB02709,Resveratrol
less,31049748,bioavailability,RES bioavailability is less than 1 owing to its low solubility and extensive intestinal and hepatic metabolism.,"Nanosized Transferosome-Based Intranasal In Situ Gel for Brain Targeting of Resveratrol: Formulation, Optimization, In Vitro Evaluation, and In Vivo Pharmacokinetic Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049748/),,1,75637,DB02709,Resveratrol
,31049748,entrapment efficiency (EE%),The optimized formula displayed spherical shape with vesicle size of 83.79 ± 2.54 nm and entrapment efficiency (EE%) of 72.58 ± 4.51%.,"Nanosized Transferosome-Based Intranasal In Situ Gel for Brain Targeting of Resveratrol: Formulation, Optimization, In Vitro Evaluation, and In Vivo Pharmacokinetic Study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049748/),%,72.58,75638,DB02709,Resveratrol
,31049748,drug release,In vitro drug release from transferosomal gel was 65.87 ± 2.12% and ex vivo permeation was 75.95 ± 3.19%.,"Nanosized Transferosome-Based Intranasal In Situ Gel for Brain Targeting of Resveratrol: Formulation, Optimization, In Vitro Evaluation, and In Vivo Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049748/),%,65.87,75639,DB02709,Resveratrol
,31049748,permeation,In vitro drug release from transferosomal gel was 65.87 ± 2.12% and ex vivo permeation was 75.95 ± 3.19%.,"Nanosized Transferosome-Based Intranasal In Situ Gel for Brain Targeting of Resveratrol: Formulation, Optimization, In Vitro Evaluation, and In Vivo Pharmacokinetic Study. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049748/),%,75.95,75640,DB02709,Resveratrol
,28467376,hepatic clearance of ε-viniferin (Vmax/Km),"In humans, the hepatic clearance of ε-viniferin (Vmax/Km) for glucuronidation and sulfation were 4.98 and 6.35 µL/min/mg protein, respectively, whereas, in rats, the hepatic clearance for glucuronidation was 20.08 vs.","In Vitro Glucuronidation and Sulfation of ε-Viniferin, a Resveratrol Dimer, in Humans and Rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28467376/),[μl] / [mg·min],4.98,77388,DB02709,Resveratrol
,28467376,hepatic clearance of ε-viniferin (Vmax/Km),"In humans, the hepatic clearance of ε-viniferin (Vmax/Km) for glucuronidation and sulfation were 4.98 and 6.35 µL/min/mg protein, respectively, whereas, in rats, the hepatic clearance for glucuronidation was 20.08 vs.","In Vitro Glucuronidation and Sulfation of ε-Viniferin, a Resveratrol Dimer, in Humans and Rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28467376/),[μl] / [mg·min],6.35,77389,DB02709,Resveratrol
,28467376,hepatic clearance,"In humans, the hepatic clearance of ε-viniferin (Vmax/Km) for glucuronidation and sulfation were 4.98 and 6.35 µL/min/mg protein, respectively, whereas, in rats, the hepatic clearance for glucuronidation was 20.08 vs.","In Vitro Glucuronidation and Sulfation of ε-Viniferin, a Resveratrol Dimer, in Humans and Rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28467376/),,20.08,77390,DB02709,Resveratrol
,16446129,flow-rate,"The analysis used a Hypersil ODS(2) C(18) column (5 microm, 4.6 mm x 250 mm) and methanol/distilled water as the mobile phase (flow-rate=1 mL/min).",High-performance liquid chromatography spectrometric analysis of trans-resveratrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446129/),[ml] / [min],1,77965,DB02709,Resveratrol
,23685116,liver targeting index,"Pharmacokinetic experiment indicated that A-B-CS-NPs rapidly assembled in liver after injection, with the highest liver targeting index of 2.70, while the modification of biotin attenuated the liver targeting ability of NPs.",Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23685116/),,2.70,84378,DB02709,Resveratrol
,30651158,flow rate,"Method: Analysis utilized C18 column using acetonitrile (ACN)-water (pH adjusted to 4.6 by 1% orthophosphoric acid) in the ratio of 55+45 (v/v) at a flow rate of 0.8 mL/min with detection at 425 and 304 nm for curcumin and resveratrol, respectively.",Simultaneous Determination of Curcumin and Resveratrol in Lipidic Nanoemulsion Formulation and Rat Plasma Using HPLC: Optimization and Application to Real Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30651158/),[ml] / [min],0.8,84612,DB02709,Resveratrol
,30651158,Extraction efficiency,"Results: Extraction efficiency of curcumin and resveratrol using ACN-methanol was 96.10-101.00% (RSD 2.49) and 95.00-99.87% (RSD 2.59), respectively.",Simultaneous Determination of Curcumin and Resveratrol in Lipidic Nanoemulsion Formulation and Rat Plasma Using HPLC: Optimization and Application to Real Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30651158/),%,96.10-101.00,84613,DB02709,Resveratrol
,30651158,Extraction efficiency,"Results: Extraction efficiency of curcumin and resveratrol using ACN-methanol was 96.10-101.00% (RSD 2.49) and 95.00-99.87% (RSD 2.59), respectively.",Simultaneous Determination of Curcumin and Resveratrol in Lipidic Nanoemulsion Formulation and Rat Plasma Using HPLC: Optimization and Application to Real Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30651158/),%,95.00-99.87,84614,DB02709,Resveratrol
,30651158,LOD,"The LOD and LOQ were found to be (0.0085 μg/mL, 0.025 μg/mL) and (0.02, 0.06), respectively.",Simultaneous Determination of Curcumin and Resveratrol in Lipidic Nanoemulsion Formulation and Rat Plasma Using HPLC: Optimization and Application to Real Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30651158/),[μg] / [ml],0.0085,84615,DB02709,Resveratrol
,30651158,LOQ,"The LOD and LOQ were found to be (0.0085 μg/mL, 0.025 μg/mL) and (0.02, 0.06), respectively.",Simultaneous Determination of Curcumin and Resveratrol in Lipidic Nanoemulsion Formulation and Rat Plasma Using HPLC: Optimization and Application to Real Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30651158/),,0.025,84616,DB02709,Resveratrol
,28736128,oral bioavailability,"Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited oral bioavailability of approximately 9%.",The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736128/),%,9,85503,DB02709,Resveratrol
,31858857,Cmax,"The Cmax value after GL-HSA-RESNPs administration was significantly higher than that of resveratrol suspension (933 ± 76.64 ng/mL vs. 618 ± 42.54 ng/mL, p < .01).","Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31858857/),[ng] / [ml],933,86137,DB02709,Resveratrol
,31858857,Cmax,"The Cmax value after GL-HSA-RESNPs administration was significantly higher than that of resveratrol suspension (933 ± 76.64 ng/mL vs. 618 ± 42.54 ng/mL, p < .01).","Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31858857/),[ng] / [ml],618,86138,DB02709,Resveratrol
,31858857,Tmax,"The Tmax value obtained after GL-HSA-RESNPs administration was significantly shorter than that after resveratrol suspension administration (0.17 ± 0.01 h vs. 0.25 ± 0.01 h, p < .001).","Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31858857/),h,0.17,86139,DB02709,Resveratrol
,31858857,Tmax,"The Tmax value obtained after GL-HSA-RESNPs administration was significantly shorter than that after resveratrol suspension administration (0.17 ± 0.01 h vs. 0.25 ± 0.01 h, p < .001).","Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31858857/),h,0.25,86140,DB02709,Resveratrol
,31330260,Tmax,"Plasmatic drug concentrations in rats observed after oral gavage indicate that both formulations provided faster resveratrol absorption than free drug, resulting in shorter Tmax values (30 min vs. 2 h).",Multicomponent self nano emulsifying delivery systems of resveratrol with enhanced pharmacokinetics profile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330260/),min,30,86156,DB02709,Resveratrol
,31330260,Tmax,"Plasmatic drug concentrations in rats observed after oral gavage indicate that both formulations provided faster resveratrol absorption than free drug, resulting in shorter Tmax values (30 min vs. 2 h).",Multicomponent self nano emulsifying delivery systems of resveratrol with enhanced pharmacokinetics profile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330260/),h,2,86157,DB02709,Resveratrol
,31739617,flux,"Compared to micronized trans-resveratrol, the trans-resveratrol/hydroxylpropylmethyl cellulose (HPMC)/poloxamer 407 (1:4:1) nanoparticles with the highest flux (0.792 μg/min/cm2) exhibited rapid absorption and showed significantly higher exposure 4 h after oral administration.",Preparation and Evaluation of Resveratrol-Loaded Composite Nanoparticles Using a Supercritical Fluid Technology for Enhanced Oral and Skin Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31739617/),[μg] / [cm2·min],0.792,88121,DB02709,Resveratrol
,14760392,IC(50),DMU 212 and resveratrol inhibited the growth of human-derived colon cancer cells HCA-7 and HT-29 in vitro with IC(50) values of between 6 and 26 microM.,"Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14760392/),μM,6 and 26,93814,DB02709,Resveratrol
,20528005,area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)),"The mean (SD) area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)) and maximum plasma concentration (C(max)) of trans-resveratrol were 3558 (2195) ng * h/mL and 1274 (790) ng/mL, respectively, after the standard breakfast.","Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528005/),[h·ng] / [ml],3558,96750,DB02709,Resveratrol
,20528005,maximum plasma concentration (C(max)),"The mean (SD) area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)) and maximum plasma concentration (C(max)) of trans-resveratrol were 3558 (2195) ng * h/mL and 1274 (790) ng/mL, respectively, after the standard breakfast.","Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528005/),[ng] / [ml],1274,96751,DB02709,Resveratrol
,27118361,oral bioavailability (BA),"Resveratrol (3,4',5-trihydroxy-trans-stilbene; RES) produces a variety of pharmacological effects; however, its oral bioavailability (BA) approaches zero.",Development of a Solid Dispersion System for Improving the Oral Bioavailability of Resveratrol in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27118361/),,zero,99573,DB02709,Resveratrol
,23690839,Serum AUC,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for IV dosing were 48.1 ± 23.8 μ g/h/mL, 18.9 ± 10.9 h, 9.54 ± 1.51 h, 47.8 ± 23.7 L/h/kg, and 5.11 ± 0.38 L/kg, respectively (mean ± SEM, n = 4) .",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),[g·μ] / [h·ml],48.1,104610,DB02709,Resveratrol
,23690839,serum t 1/2,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for IV dosing were 48.1 ± 23.8 μ g/h/mL, 18.9 ± 10.9 h, 9.54 ± 1.51 h, 47.8 ± 23.7 L/h/kg, and 5.11 ± 0.38 L/kg, respectively (mean ± SEM, n = 4) .",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),h,9.54,104611,DB02709,Resveratrol
,23690839,Vd,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for IV dosing were 48.1 ± 23.8 μ g/h/mL, 18.9 ± 10.9 h, 9.54 ± 1.51 h, 47.8 ± 23.7 L/h/kg, and 5.11 ± 0.38 L/kg, respectively (mean ± SEM, n = 4) .",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),[l] / [h·kg],47.8,104612,DB02709,Resveratrol
,23690839,Vd,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for IV dosing were 48.1 ± 23.8 μ g/h/mL, 18.9 ± 10.9 h, 9.54 ± 1.51 h, 47.8 ± 23.7 L/h/kg, and 5.11 ± 0.38 L/kg, respectively (mean ± SEM, n = 4) .",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),[l] / [kg],5.11,104613,DB02709,Resveratrol
,23690839,Serum AUC,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),[g·μ] / [h·ml],229,104614,DB02709,Resveratrol
,23690839,serum t 1/2,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),h,73.3,104615,DB02709,Resveratrol
,23690839,serum t 1/2,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),h,20.6,104616,DB02709,Resveratrol
,23690839,urine t 1/2,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),h,73.3,104617,DB02709,Resveratrol
,23690839,Cltotal,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),h,73.3,104618,DB02709,Resveratrol
,23690839,Vd,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),[l] / [h·kg],0.48,104619,DB02709,Resveratrol
,23690839,Vd,"Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 ± 44.6 μ g/h/mL, 73.3 ± 8.91 h, 20.6 ± 3.01 h, 0.48 ± 0.008 L/h/kg, and 52.0 ± 10.5 L/kg, respectively (mean ± SEM, n = 4).",Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),[l] / [kg],52.0,104620,DB02709,Resveratrol
,23690839,Bioavailability,Bioavailability of the stilbene was determined to be 50.6% ± 10.0%.,Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese medicinal plants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690839/),%,50.6,104621,DB02709,Resveratrol
,25392203,globule diameter,"The homogenized formulation, which contained 150 mg ml(-1) of resveratrol, showed spherical globules with an average globule diameter of 102 ± 1.46 nm, a least poly dispersity index of 0.158 ± 0.02 and optimal zeta potential values of -35 ± 0.02.",Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392203/),nm,102,105504,DB02709,Resveratrol
,25392203,cumulative percentage drug release,"The cumulative percentage drug release for the pre-homogenized resveratrol suspension, pre-homogenized nanoemulsion and post-homogenized nanoemulsion were 24.18 ± 2.30%, 54.32 ± 0.95% and 88.57 ± 1.92%, respectively, after 24 h.",Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392203/),%,24.18,105505,DB02709,Resveratrol
,25392203,cumulative percentage drug release,"The cumulative percentage drug release for the pre-homogenized resveratrol suspension, pre-homogenized nanoemulsion and post-homogenized nanoemulsion were 24.18 ± 2.30%, 54.32 ± 0.95% and 88.57 ± 1.92%, respectively, after 24 h.",Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392203/),%,54.32,105506,DB02709,Resveratrol
,25392203,cumulative percentage drug release,"The cumulative percentage drug release for the pre-homogenized resveratrol suspension, pre-homogenized nanoemulsion and post-homogenized nanoemulsion were 24.18 ± 2.30%, 54.32 ± 0.95% and 88.57 ± 1.92%, respectively, after 24 h.",Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392203/),%,88.57,105507,DB02709,Resveratrol
,25392203,cumulative percentage drug release,The ex vivo release also showed the cumulative percentage drug release of 85.48 ± 1.34% at 24 h.,Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392203/),%,85.48,105508,DB02709,Resveratrol
,25392203,brain/blood ratio,Pharmacokinetic studies showed the higher concentration of the drug in the brain (brain/blood ratio: 2.86 ± 0.70) following intranasal administration of the optimized nanoemulsion.,Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392203/),,2.86,105509,DB02709,Resveratrol
,11879711,specific activities,Optimisation of several parameters such as the quantity of precursor applied and the duration of metabolism led to incorporation yields of 15% and to specific activities of 875 mu Ci g(-1) in stilbenes.,Carbon-14 biolabelling of wine polyphenols in Vitis vinifera cell suspension cultures. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879711/),[ci·mu] / [g],875,111943,DB02709,Resveratrol
,11879711,specific activity,"Both trans- and cis-resveratrols were easily obtained by enzymatic hydrolysis of their corresponding glucosides, with specific activity of 1200-1400 mu Ci g(-1).",Carbon-14 biolabelling of wine polyphenols in Vitis vinifera cell suspension cultures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879711/),[ci·mu] / [g],1200-1400,111944,DB02709,Resveratrol
,12739983,elimination half-life (t((1/2))),Vitamin C is not protein-bound and is eliminated with an elimination half-life (t((1/2))) of 10 hours.,Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,10,111974,DB02709,Resveratrol
,12739983,bioavailability,"The bioavailability of all-rac-alpha-tocopherol is estimated to be 50% of R,R,R-alpha-tocopherol.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),%,50,111975,DB02709,Resveratrol
,12739983,t((1/2)),"Elimination of alpha-tocopherol takes several days with a t((1/2)) of 81 and 73 hours for R,R,R-alpha-tocopherol and all-rac-alpha-tocopherol, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,81,111976,DB02709,Resveratrol
,12739983,t((1/2)),"Elimination of alpha-tocopherol takes several days with a t((1/2)) of 81 and 73 hours for R,R,R-alpha-tocopherol and all-rac-alpha-tocopherol, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,73,111977,DB02709,Resveratrol
,12739983,t((1/2)),"The t((1/2)) of tocotrienols is short, ranging from 3.8-4.4 hours for gamma- and alpha-tocotrienol, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,3.8-4.4,111978,DB02709,Resveratrol
,12739983,t((1/2)),"Elimination of carotenoids takes several days with a t((1/2)) of 5-7 and 2-3 days for beta-carotene and lycopene, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),d,5-7,111979,DB02709,Resveratrol
,12739983,t((1/2)),"Elimination of carotenoids takes several days with a t((1/2)) of 5-7 and 2-3 days for beta-carotene and lycopene, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),d,2-3,111980,DB02709,Resveratrol
,12739983,bioconversion,"The bioconversion of beta-carotene to retinal is dose-dependent, and ranges between 27% and 2% for a 6 and 126mg dose, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),%,27,111981,DB02709,Resveratrol
,12739983,bioconversion,"The bioconversion of beta-carotene to retinal is dose-dependent, and ranges between 27% and 2% for a 6 and 126mg dose, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),%,2,111982,DB02709,Resveratrol
,12739983,t((1/2)),The t((1/2)) ranges from 12-19 hours.,Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,12-19,111983,DB02709,Resveratrol
,12739983,t((1/2)),The bioavailabillity of catechins is low and they are eliminated with a t((1/2)) of 2-4 hours.,Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,2-4,111984,DB02709,Resveratrol
low,24827888,IC50,RGC has demonstrated a strong inhibitory effect on LDL oxidation with IC50 as low as 8.0 μg/ml.,A novel red grape cells complex: health effects and bioavailability of natural resveratrol. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827888/),[μg] / [ml],8.0,114646,DB02709,Resveratrol
,32993976,binding rate,Folic acid was conjugated to bovine serum albumin by amide bond at a binding rate of 9.46 ± 0.49 folate molecules per bovine serum albumin.,"Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),molecules,9.46,114999,DB02709,Resveratrol
,32993976,entrapment efficiency,"The particle size and entrapment efficiency of the developed nanoparticles was found to be 291.37 ± 3.81 nm and 91.96 ± 1.83%, respectively.","Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),%,91.96,115000,DB02709,Resveratrol
>,32993976,circulation time,The pharmacokinetics studies after intravenous administration in healthy Wistar rats depicted that lipoprotein mimicking nanoparticles presented the longer circulation time (>48 h) compared to free drug which disappeared in few hours (6 h).,"Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),h,48,115001,DB02709,Resveratrol
,32993976,circulation time,The pharmacokinetics studies after intravenous administration in healthy Wistar rats depicted that lipoprotein mimicking nanoparticles presented the longer circulation time (>48 h) compared to free drug which disappeared in few hours (6 h).,"Resveratrol-loaded folate targeted lipoprotein-mimetic nanoparticles with improved cytotoxicity, antioxidant activity and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32993976/),h,6,115002,DB02709,Resveratrol
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,56.75,117862,DB02709,Resveratrol
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,69.07,117863,DB02709,Resveratrol
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,14.22,117864,DB02709,Resveratrol
,28820428,Tmax,Glucosamine was detected up to 8 h post-dose with a Tmax of 2 h and Cmax of 9.69 μg/mL.,Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820428/),h,2,120987,DB02709,Resveratrol
,28820428,Cmax,Glucosamine was detected up to 8 h post-dose with a Tmax of 2 h and Cmax of 9.69 μg/mL.,Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820428/),[μg] / [ml],9.69,120988,DB02709,Resveratrol
,26633237,maximum plasma concentration (Cmax),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),[μg] / [ml],1.73 to 2.91,122525,DB02709,Resveratrol
,26633237,area under the curve (AUC),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),[g·h] / [ml],5.05 to 9.95,122526,DB02709,Resveratrol
,26633237,half life (T1/2),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),h,1.12 to 1.76,122527,DB02709,Resveratrol
,26633237,elimination rate constant (Kel ),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),1/[h],0.71 to 0.41,122528,DB02709,Resveratrol
,26633237,apparent oral clearance (CL/F),"Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 g h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel ) (0.71 to 0.41 h(-1)), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control.",Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633237/),[l] / [h],14.58 to 6.48,122529,DB02709,Resveratrol
,26771130,clearance (Cl,"Upon intravenous administration (5 or 10mg/kg), pinostilbene displayed rapid clearance (Cl=129±42 or 107±31ml/min/kg) and extremely short mean transit time (MTT=6.24±0.41 or 8.52±1.38min).",Determination of pinostilbene in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26771130/),[ml] / [kg·min],129,123761,DB02709,Resveratrol
,26771130,clearance (Cl,"Upon intravenous administration (5 or 10mg/kg), pinostilbene displayed rapid clearance (Cl=129±42 or 107±31ml/min/kg) and extremely short mean transit time (MTT=6.24±0.41 or 8.52±1.38min).",Determination of pinostilbene in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26771130/),[ml] / [kg·min],107,123762,DB02709,Resveratrol
,26771130,mean transit time (MTT,"Upon intravenous administration (5 or 10mg/kg), pinostilbene displayed rapid clearance (Cl=129±42 or 107±31ml/min/kg) and extremely short mean transit time (MTT=6.24±0.41 or 8.52±1.38min).",Determination of pinostilbene in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26771130/),min,6.24,123763,DB02709,Resveratrol
,26771130,mean transit time (MTT,"Upon intravenous administration (5 or 10mg/kg), pinostilbene displayed rapid clearance (Cl=129±42 or 107±31ml/min/kg) and extremely short mean transit time (MTT=6.24±0.41 or 8.52±1.38min).",Determination of pinostilbene in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26771130/),min,8.52,123764,DB02709,Resveratrol
,26771130,F,"After oral dosing (50mg/kg), the bioavailability of pinostilbene was limited but highly erratic (F=1.87±2.67%).",Determination of pinostilbene in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26771130/),%,1.87,123765,DB02709,Resveratrol
,10798302,flow-rate,"Chromatographic separation was achieved within 12 min using a C18 (100x2.0 mm) 3 microm column with a mobile phase containing 20 mM sodium acetate, 0.5 mM EDTA, pH 4.5 and 21% acetonitrile at a flow-rate of 0.4 ml/min.",Liquid chromatography with multichannel electrochemical detection for the determination of trans-resveratrol in rat blood utilizing an automated blood sampling device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10798302/),[ml] / [min],0.4,126905,DB02709,Resveratrol
,10798302,signal-to-noise ratio,The limit of detection was 2 ng/ml at a signal-to-noise ratio of 3:1 and the limit of quantitation was 4 ng/ml.,Liquid chromatography with multichannel electrochemical detection for the determination of trans-resveratrol in rat blood utilizing an automated blood sampling device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10798302/),,3:1,126906,DB02709,Resveratrol
,20886884,t(max),The t(max) ranged from 0.9 h for compounds 2 and 5 to 2 h for compound 3.,Pharmacokinetic study of trans-resveratrol in adult pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),h,0.9,126979,DB02709,Resveratrol
,20886884,t(max),The t(max) ranged from 0.9 h for compounds 2 and 5 to 2 h for compound 3.,Pharmacokinetic study of trans-resveratrol in adult pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),h,5,126980,DB02709,Resveratrol
,20886884,t(max),The t(max) ranged from 0.9 h for compounds 2 and 5 to 2 h for compound 3.,Pharmacokinetic study of trans-resveratrol in adult pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),h,2,126981,DB02709,Resveratrol
,20886884,C(max),"The highest C(max) value was 2223 ng/mL (5.5 μM) for metabolite 5, which was 2.6-, 3.3-, and 12-fold higher than that for metabolites 6, 2, and 3, respectively.",Pharmacokinetic study of trans-resveratrol in adult pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),[ng] / [ml],2223,126982,DB02709,Resveratrol
,20886884,C(max),"The highest C(max) value was 2223 ng/mL (5.5 μM) for metabolite 5, which was 2.6-, 3.3-, and 12-fold higher than that for metabolites 6, 2, and 3, respectively.",Pharmacokinetic study of trans-resveratrol in adult pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),μM,5.5,126983,DB02709,Resveratrol
,20886884,Peak plasma levels,Peak plasma levels of RES (53 ng/mL; 0.23 μM) were detected 0.5 h after RES ingestion.,Pharmacokinetic study of trans-resveratrol in adult pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),[ng] / [ml],53,126984,DB02709,Resveratrol
,20886884,Peak plasma levels,Peak plasma levels of RES (53 ng/mL; 0.23 μM) were detected 0.5 h after RES ingestion.,Pharmacokinetic study of trans-resveratrol in adult pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20886884/),μM,0.23,126985,DB02709,Resveratrol
,28194730,ζ,The optimized NCs were successfully accomplished in a sub-micron particle size (110.28 ± 12.55 nm) with high ζ-potential (-32.96 ± 3.85 mV) value.,Preparation and in-vitro/in-vivo characterization of trans-resveratrol nanocrystals for oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28194730/),m,32.96,128603,DB02709,Resveratrol
,31234063,entrapment efficiency,The optimized RSV-NLCs exhibited an optimum particle size of 88.3 ± 3.1 nm and high entrapment efficiency of 88.0 ± 2.6%.,"Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31234063/),%,88.0,131433,DB02709,Resveratrol
,31234063,AUC,In vivo pharmacokinetic studies demonstrated a nine-fold increase in AUC values obtained with RSV-FA-NLCs (57.92 ± 4.15 μg h/mLh) in comparison to free RSV (6.37 ± 1.16 μg h/mLh).,"Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31234063/),[h·μg] / [mlh],57.92,131434,DB02709,Resveratrol
,31234063,AUC,In vivo pharmacokinetic studies demonstrated a nine-fold increase in AUC values obtained with RSV-FA-NLCs (57.92 ± 4.15 μg h/mLh) in comparison to free RSV (6.37 ± 1.16 μg h/mLh).,"Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31234063/),[h·μg] / [mlh],6.37,131435,DB02709,Resveratrol
,21116625,bioavailable,"Resveratrol and pterostilbene were approximately 20 and 80% bioavailable, respectively.","Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116625/),%,20,132585,DB02709,Resveratrol
,21116625,bioavailable,"Resveratrol and pterostilbene were approximately 20 and 80% bioavailable, respectively.","Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116625/),%,80,132586,DB02709,Resveratrol
,15333514,peak plasma levels,"The absorption of a dietary relevant 25-mg oral dose was at least 70%, with peak plasma levels of resveratrol and metabolites of 491 +/- 90 ng/ml (about 2 microM) and a plasma half-life of 9.2 +/- 0.6 h.",High absorption but very low bioavailability of oral resveratrol in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333514/),[ng] / [ml],491,132616,DB02709,Resveratrol
,15333514,plasma half-life,"The absorption of a dietary relevant 25-mg oral dose was at least 70%, with peak plasma levels of resveratrol and metabolites of 491 +/- 90 ng/ml (about 2 microM) and a plasma half-life of 9.2 +/- 0.6 h.",High absorption but very low bioavailability of oral resveratrol in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333514/),h,9.2,132617,DB02709,Resveratrol
,30417385,inhibition constant (Ki ),"Probenecid inhibition of resveratrol 3-O-glucuronidation was predominantly noncompetitive, with an inhibition constant (Ki ) averaging 3.1 mm.",Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30417385/),mm,3.1,135162,DB02709,Resveratrol
,20572052,minimum Glu concentration,"Low cross-linking solution pH (1.5), minimum Glu concentration (2.5%) and cross-linking time (2 h) were crucial to exhibit colon-specific drug release.",Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572052/),%,2.5,140819,DB02709,Resveratrol
>,20684731,en,Microparticles were spherical with <1 mm diameter and encapsulation efficiencies of >94%.,Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20684731/),%,94,143356,DB02709,Resveratrol
,22079044,flow rate,Chromatographic separation was performed using a C18 column (30 mm × 2.0 mm) at a flow rate of 0.25 mL/min.,Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22079044/),[ml] / [min],0.25,143422,DB02709,Resveratrol
,22079044,Total run time,Total run time was 12 min for each run with retention times of about 4-5 min for all analytes.,Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22079044/),min,12,143423,DB02709,Resveratrol
,22079044,retention times,Total run time was 12 min for each run with retention times of about 4-5 min for all analytes.,Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22079044/),min,4-5,143424,DB02709,Resveratrol
,22079044,Peak plasma resveratrol concentration (C(max)),"Peak plasma resveratrol concentration (C(max)) for most animals was observed within 1-5 h of dosing, with group mean values in the 1.7-9.9 μg/mL (7.5-43 μM) range.",Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22079044/),[μg] / [ml],1.7-9.9,143425,DB02709,Resveratrol
,22079044,Area under the plasma concentration-time curve (AUC),"Area under the plasma concentration-time curve (AUC) mean values for resveratrol ranged from 3.6 to 44 h μg/mL for all study groups and were generally proportional to the dose, with no consistent statistically significant changes observed for gender or number of doses.",Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22079044/),[h·μg] / [ml],3.6 to 44,143426,DB02709,Resveratrol
,30038494,polydispersity index,The resulting RES-GNPs were 108.4 nm around in particle size with a polydispersity index of 0.217.,Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30038494/),,0.217,145987,DB02709,Resveratrol
up to,30038494,oral bioavailability,"After oral administration, RES-GNPs significantly enhanced the oral bioavailability of RES, up to 335.7% relative to RES suspensions.",Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30038494/),%,335.7,145988,DB02709,Resveratrol
,27566226,drug targeting efficiency,The drug targeting efficiency (458.2%) and direct transport percentages (78.18%) demonstrated direct delivery via the nose-brain pathway.,Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566226/),%,458.2,146830,DB02709,Resveratrol
,27566226,direct transport percentages,The drug targeting efficiency (458.2%) and direct transport percentages (78.18%) demonstrated direct delivery via the nose-brain pathway.,Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566226/),%,78.18,146831,DB02709,Resveratrol
,31861173,zeta potential,The initial particle size (z-average) was 46.3 nm and the zeta potential was -38.02 mV.,"Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31861173/),m,38.02,151862,DB02709,Resveratrol
,28369685,oral bioavailability,Its oral bioavailability was approximately 50% higher than resveratrol.,"Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369685/),%,50,154034,DB02709,Resveratrol
,12126761,Half-life,"Half-life of RES in plasma, after i.v. administration of 20 mg t-RES/kg b.wt., was very short (e.g., 14.4 min in rabbits).",Inhibition of cancer growth by resveratrol is related to its low bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12126761/),min,14.4,159148,DB02709,Resveratrol
<,12126761,Extravascular levels,"Extravascular levels (brain, lung, liver, and kidney) of RES, which paralleled those in plasma, were always < 1 nmol/g fresh tissue.",Inhibition of cancer growth by resveratrol is related to its low bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12126761/),[nM] / [g],1,159149,DB02709,Resveratrol
,25004068,flow rate,Chromatographic separation was obtained with a reversed-phase HPLC column through a 12.5-min gradient delivery of a mixture of acetonitrile and water at the flow rate of 1.5 mL/min at 50 °C.,"Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),[ml] / [min],1.5,159295,DB02709,Resveratrol
,25004068,volume of distribution of the central compartment (Vc,"Upon single intravenous administration (4 mg/kg), 2,3-DMS had a medium volume of distribution of the central compartment (Vc = 2.71 ± 0.51 L/kg), quite rapid clearance (Cl = 52.0 ± 7.0 mL/min/kg), moderate mean transit time (MTT0→last = 131.0 ± 4.5 min) but a fairly long terminal elimination half-life (t1/2 λZ = 288.9 ± 92.9 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),[l] / [kg],2.71,159296,DB02709,Resveratrol
,25004068,clearance (Cl,"Upon single intravenous administration (4 mg/kg), 2,3-DMS had a medium volume of distribution of the central compartment (Vc = 2.71 ± 0.51 L/kg), quite rapid clearance (Cl = 52.0 ± 7.0 mL/min/kg), moderate mean transit time (MTT0→last = 131.0 ± 4.5 min) but a fairly long terminal elimination half-life (t1/2 λZ = 288.9 ± 92.9 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),[ml] / [kg·min],52.0,159297,DB02709,Resveratrol
,25004068,mean transit time (MTT0→last,"Upon single intravenous administration (4 mg/kg), 2,3-DMS had a medium volume of distribution of the central compartment (Vc = 2.71 ± 0.51 L/kg), quite rapid clearance (Cl = 52.0 ± 7.0 mL/min/kg), moderate mean transit time (MTT0→last = 131.0 ± 4.5 min) but a fairly long terminal elimination half-life (t1/2 λZ = 288.9 ± 92.9 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),min,131.0,159298,DB02709,Resveratrol
,25004068,terminal elimination half-life (t1/2 λZ,"Upon single intravenous administration (4 mg/kg), 2,3-DMS had a medium volume of distribution of the central compartment (Vc = 2.71 ± 0.51 L/kg), quite rapid clearance (Cl = 52.0 ± 7.0 mL/min/kg), moderate mean transit time (MTT0→last = 131.0 ± 4.5 min) but a fairly long terminal elimination half-life (t1/2 λZ = 288.9 ± 92.9 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),min,288.9,159299,DB02709,Resveratrol
,25004068,distribution (Vc,"Interestingly, 3,4-DMS displayed a pharmacokinetic profile apparently distinct from 2,3-DMS and it had more extensive distribution (Vc = 5.58 ± 1.73 L/kg), faster clearance (Cl = 143.4 ± 40.5 mL/min/kg) and shorter residence (MTT0→last = 61.4 ± 27.1 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),[l] / [kg],5.58,159300,DB02709,Resveratrol
,25004068,clearance (Cl,"Interestingly, 3,4-DMS displayed a pharmacokinetic profile apparently distinct from 2,3-DMS and it had more extensive distribution (Vc = 5.58 ± 1.73 L/kg), faster clearance (Cl = 143.4 ± 40.5 mL/min/kg) and shorter residence (MTT0→last = 61.4 ± 27.1 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),[ml] / [kg·min],143.4,159301,DB02709,Resveratrol
,25004068,residence (MTT0→last,"Interestingly, 3,4-DMS displayed a pharmacokinetic profile apparently distinct from 2,3-DMS and it had more extensive distribution (Vc = 5.58 ± 1.73 L/kg), faster clearance (Cl = 143.4 ± 40.5 mL/min/kg) and shorter residence (MTT0→last = 61.4 ± 27.1 min).","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),min,61.4,159302,DB02709,Resveratrol
,25004068,Cmax,"Following single oral administration (10 mg/kg), 2,3-DMS had low and erratic plasma exposure (Cmax = 37.5 ± 23.7 ng/mL) and poor oral bioavailability (2.22% ± 2.13%) while the oral bioavailability of 3,4-DMS was even poorer than 2,3-DMS.","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),[ng] / [ml],37.5,159303,DB02709,Resveratrol
,25004068,oral bioavailability,"Following single oral administration (10 mg/kg), 2,3-DMS had low and erratic plasma exposure (Cmax = 37.5 ± 23.7 ng/mL) and poor oral bioavailability (2.22% ± 2.13%) while the oral bioavailability of 3,4-DMS was even poorer than 2,3-DMS.","Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25004068/),%,2.22,159304,DB02709,Resveratrol
,24735927,flow rate,"After one-step protein precipitation with methanol, the analyte and IS were separated on an ODS column by gradient elution with mobile phase of acetonitrile-0.2% formic acid at a flow rate of 0.3mL/min.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),[ml] / [min],0.3,160342,DB02709,Resveratrol
>,24735927,m/z,"Negative electrospray ionization was performed using multiple reactions monitoring (MRM) mode with transitions of m/z 453.0>410.9 for TVN, and m/z 168.0>132.0 for IS.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),,453.0,160343,DB02709,Resveratrol
>,24735927,m/z,"Negative electrospray ionization was performed using multiple reactions monitoring (MRM) mode with transitions of m/z 453.0>410.9 for TVN, and m/z 168.0>132.0 for IS.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),,410.9,160344,DB02709,Resveratrol
>,24735927,m/z,"Negative electrospray ionization was performed using multiple reactions monitoring (MRM) mode with transitions of m/z 453.0>410.9 for TVN, and m/z 168.0>132.0 for IS.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),,168.0,160345,DB02709,Resveratrol
>,24735927,m/z,"Negative electrospray ionization was performed using multiple reactions monitoring (MRM) mode with transitions of m/z 453.0>410.9 for TVN, and m/z 168.0>132.0 for IS.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),,132.0,160346,DB02709,Resveratrol
,24735927,recoveries,"The mean recoveries for TVN and IS were 91.05% and 96.68%, respectively.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),%,91.05,160347,DB02709,Resveratrol
,24735927,recoveries,"The mean recoveries for TVN and IS were 91.05% and 96.68%, respectively.","Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),%,96.68,160348,DB02709,Resveratrol
,24735927,oral absolute bioavailability,The oral absolute bioavailability of TVN was 14.2% in rat.,"Development and validation of a sensitive and selective LC-MS/MS method for the determination of trans δ-veniferin, a resveratrol dehydrodimer, in rat plasma and its application to pharmacokinetics and bioavailability studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735927/),%,14.2,160349,DB02709,Resveratrol
<,25102112,half-life,"However, because of its low half-life (<0.25 h) the molecule is difficult to achieve the therapeutic concentration at the site of action.",In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102112/),h,0.25,164581,DB02709,Resveratrol
,25102112,particle size,"The mean particle size and zeta potential of the optimized formulation (drug-lipid ratio of 1:10) were 248.30 ± 3.80nm and -25.49 ± 0.49mV, respectively.",In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102112/),nm,248.30,164582,DB02709,Resveratrol
,25102112,zeta potential,"The mean particle size and zeta potential of the optimized formulation (drug-lipid ratio of 1:10) were 248.30 ± 3.80nm and -25.49 ± 0.49mV, respectively.",In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102112/),mv,-,164583,DB02709,Resveratrol
,25102112,zeta potential,"The mean particle size and zeta potential of the optimized formulation (drug-lipid ratio of 1:10) were 248.30 ± 3.80nm and -25.49 ± 0.49mV, respectively.",In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102112/),mv,25.49,164584,DB02709,Resveratrol
≤,32205187,Tmax_predicted,Following gavage administration Tmax_predicted values were ≤ 263 min for both species and sexes.,Comparative toxicokinetics of Trans-resveratrol and its major metabolites in Harlan Sprague Dawley rats and B6C3F1/N mice following oral and intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32205187/),min,263,167052,DB02709,Resveratrol
,32205187,bioavailability,"The bioavailability of RES was low, ~12-31% and ~2-6% for rats and mice, respectively, with no apparent difference between sexes.",Comparative toxicokinetics of Trans-resveratrol and its major metabolites in Harlan Sprague Dawley rats and B6C3F1/N mice following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32205187/),%,12-31,167053,DB02709,Resveratrol
,32205187,bioavailability,"The bioavailability of RES was low, ~12-31% and ~2-6% for rats and mice, respectively, with no apparent difference between sexes.",Comparative toxicokinetics of Trans-resveratrol and its major metabolites in Harlan Sprague Dawley rats and B6C3F1/N mice following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32205187/),%,2-6,167054,DB02709,Resveratrol
,31546400,zeta potential,"Homogenous particle size distributions at the desired nanoscale interval (ca. 116-220 nm; polydispersity index below 0.15), good colloidal (zeta potential magnitudes ca. ± 20-30 mV) and chemical stabilizations, high encapsulation efficiency (above 90%) together with an excellent cytocompatibility with Caco-2 cells (cell viability above 90%) were observed for all the nanoformulations.",Sonication-assisted Layer-by-Layer self-assembly nanoparticles for resveratrol delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31546400/),m,20-30,170476,DB02709,Resveratrol
,24625210,AUC,"The AUC for total piceatannol was less than that for total resveratrol, whereas the AUC for piceatannol (8.6 μmol·h/L) after piceatannol and resveratrol coadministration was 2.1 times greater than that for resveratrol (4.1 μmol·h/L).",Absorption and metabolism of piceatannol in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24625210/),[h·μM] / [l],8.6,182239,DB02709,Resveratrol
,24625210,AUC,"The AUC for total piceatannol was less than that for total resveratrol, whereas the AUC for piceatannol (8.6 μmol·h/L) after piceatannol and resveratrol coadministration was 2.1 times greater than that for resveratrol (4.1 μmol·h/L).",Absorption and metabolism of piceatannol in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24625210/),[h·μM] / [l],4.1,182240,DB02709,Resveratrol
,29471224,clearance (Cl,"Upon intravenous administration (4 or 10 mg/kg), DRG displayed very rapid clearance (Cl = 338 ± 66 or 275 ± 30 ml/min/kg) and short mean residence time (MRT = 12.9 ± 4.7 or 10.4 ± 0.5 min).",Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29471224/),[ml] / [kg·min],338,182389,DB02709,Resveratrol
,29471224,clearance (Cl,"Upon intravenous administration (4 or 10 mg/kg), DRG displayed very rapid clearance (Cl = 338 ± 66 or 275 ± 30 ml/min/kg) and short mean residence time (MRT = 12.9 ± 4.7 or 10.4 ± 0.5 min).",Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29471224/),[ml] / [kg·min],275,182390,DB02709,Resveratrol
,29471224,mean residence time (MRT,"Upon intravenous administration (4 or 10 mg/kg), DRG displayed very rapid clearance (Cl = 338 ± 66 or 275 ± 30 ml/min/kg) and short mean residence time (MRT = 12.9 ± 4.7 or 10.4 ± 0.5 min).",Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29471224/),min,12.9,182391,DB02709,Resveratrol
,29471224,mean residence time (MRT,"Upon intravenous administration (4 or 10 mg/kg), DRG displayed very rapid clearance (Cl = 338 ± 66 or 275 ± 30 ml/min/kg) and short mean residence time (MRT = 12.9 ± 4.7 or 10.4 ± 0.5 min).",Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29471224/),min,10.4,182392,DB02709,Resveratrol
<,29471224,absolute bioavailability (F,"After oral administration of DRG fully solubilized by 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), the plasma profiles of DRG were highly erratic with a low absolute bioavailability (F < 9.83 ± 5.31%).",Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29471224/),%,9.83,182393,DB02709,Resveratrol
,30834522,relative uptake rate (Re ),"In addition, in the study of liver targeting, the relative uptake rate (Re ) of Gal-Res in the liver (2.006) is the largest.","Synthesis, cytotoxicity and liver targeting of 3-O-β-D-Galactosylated Resveratrol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30834522/),,2.006,184245,DB02709,Resveratrol
,30834522,drug targeting efficiency (Te,The drug targeting efficiency (Te ; 38.924%) of Gal-Res was greater than that of Res.,"Synthesis, cytotoxicity and liver targeting of 3-O-β-D-Galactosylated Resveratrol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30834522/),%,38.924,184246,DB02709,Resveratrol
,21520090,clearance,"Upon single intravenous administration (5 mg/kg), RTE displayed moderate clearance (35.5 ± 5.3 mL/min/kg) and a fairly long terminal elimination half-life (511 ± 136 min); dose escalation (5-20 mg/kg) did not cause nonlinear pharmacokinetics.","Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21520090/),[ml] / [kg·min],35.5,185729,DB02709,Resveratrol
,21520090,terminal elimination half-life,"Upon single intravenous administration (5 mg/kg), RTE displayed moderate clearance (35.5 ± 5.3 mL/min/kg) and a fairly long terminal elimination half-life (511 ± 136 min); dose escalation (5-20 mg/kg) did not cause nonlinear pharmacokinetics.","Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21520090/),min,511,185730,DB02709,Resveratrol
<,21520090,bioavailability,"When given orally in suspension (60 mg/kg), RTE was poorly absorbed with negligible bioavailability (< 1.5%), fasting further decreased its bioavailability (<1%).","Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21520090/),%,1.5,185731,DB02709,Resveratrol
<,21520090,bioavailability,"When given orally in suspension (60 mg/kg), RTE was poorly absorbed with negligible bioavailability (< 1.5%), fasting further decreased its bioavailability (<1%).","Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21520090/),%,1,185732,DB02709,Resveratrol
,21520090,bioavailability,"However, when administered in a solution formulated with randomly methylated-β-cyclodextrin (15 mg/kg), RTE was rapidly absorbed with good bioavailability (46.5 ± 4.8%).","Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21520090/),%,46.5,185733,DB02709,Resveratrol
,21520090,bioavailability,Dose escalation resulted in increased bioavailability (64.6 ± 8.0%) at the dose of 60 mg/kg.,"Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21520090/),%,64.6,185734,DB02709,Resveratrol
,18300476,limit of detection (S/N: 3/1),The limit of detection (S/N: 3/1) for BTM-0512 was 0.005 microg x mL(-1) for plasma.,RP-HPLC study of resveratrol derivative (BTM-0512) in rat plasma and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300476/),[μg] / [ml],0.005,188477,DB02709,Resveratrol
,18300476,accuracy,"Mean accuracy and absolute recoveries of BTM-0512 ranged from 95.3% - 100.1% and 95.9% - 100.9% for plasma and tissues, respectively.",RP-HPLC study of resveratrol derivative (BTM-0512) in rat plasma and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300476/),%,95.3,188478,DB02709,Resveratrol
,18300476,absolute recoveries,"Mean accuracy and absolute recoveries of BTM-0512 ranged from 95.3% - 100.1% and 95.9% - 100.9% for plasma and tissues, respectively.",RP-HPLC study of resveratrol derivative (BTM-0512) in rat plasma and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300476/),%,100,188479,DB02709,Resveratrol
,18300476,absolute recoveries,"Mean accuracy and absolute recoveries of BTM-0512 ranged from 95.3% - 100.1% and 95.9% - 100.9% for plasma and tissues, respectively.",RP-HPLC study of resveratrol derivative (BTM-0512) in rat plasma and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300476/),%,95.9,188480,DB02709,Resveratrol
,18300476,absolute recoveries,"Mean accuracy and absolute recoveries of BTM-0512 ranged from 95.3% - 100.1% and 95.9% - 100.9% for plasma and tissues, respectively.",RP-HPLC study of resveratrol derivative (BTM-0512) in rat plasma and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300476/),%,100,188481,DB02709,Resveratrol
,26902951,zeta potential,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),mv,-,191496,DB02709,Resveratrol
,26902951,zeta potential,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),mv,13.56,191497,DB02709,Resveratrol
,26902951,entrapment efficiency,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),%,75.23,191498,DB02709,Resveratrol
,26902951,maximum % release,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),%,80.53,191499,DB02709,Resveratrol
,26902951,AUC0→∞,In vivo studies revealed nearly five-fold increase in the bioavailability of SR-1 (AUC0→∞=3411 ± 170.34 µg/ml/h) as compared to RV suspension (AUC0→∞=653.5 ± 30.10 µg/ml/h).,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),[μg] / [h·ml],3411,191500,DB02709,Resveratrol
,26902951,AUC0→∞,In vivo studies revealed nearly five-fold increase in the bioavailability of SR-1 (AUC0→∞=3411 ± 170.34 µg/ml/h) as compared to RV suspension (AUC0→∞=653.5 ± 30.10 µg/ml/h).,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),[μg] / [h·ml],653.5,191501,DB02709,Resveratrol
,32502955,complete run time,"To investigate the pharmacokinetic characteristics and absolute bioavailability of α-viniferin in rats, using naringenin as an internal standard (IS), a rapid HPLC-MS/MS method of 5 min complete run time was developed.",Pharmacokinetic and bioavailability studies of α-viniferin after intravenous and oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502955/),min,5,191916,DB02709,Resveratrol
,32502955,flow rate,"The chromatographic separation of α-viniferin and naringenin were accomplished with Waters XBridge™ C18 column (2.1 mm × 100 mm, 3.5 μm) and the mobile phase were acetonitrile and 0.1 % formic acid at a flow rate of 0.3 mL/min.",Pharmacokinetic and bioavailability studies of α-viniferin after intravenous and oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502955/),[ml] / [min],0.3,191917,DB02709,Resveratrol
,32502955,Oral bioavailability,Oral bioavailability of α-viniferin was 4.2 %.,Pharmacokinetic and bioavailability studies of α-viniferin after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502955/),%,4.2,191918,DB02709,Resveratrol
,34405290,drug loading (DL %,The drug loading (DL %) and entrapment efficiency (EE %) of Gal-Res NPs were 46.80% and 88.06%.,"Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),%,46.80,192499,DB02709,Resveratrol
,34405290,entrapment efficiency (EE %),The drug loading (DL %) and entrapment efficiency (EE %) of Gal-Res NPs were 46.80% and 88.06%.,"Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),%,88.06,192500,DB02709,Resveratrol
,34405290,particle,"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),nm,179.38,192501,DB02709,Resveratrol
,34405290,polydispersity index (PDI),"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),mv,0.129,192502,DB02709,Resveratrol
,34405290,Zeta potential,"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),mv,-,192503,DB02709,Resveratrol
,34405290,Zeta potential,"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),mv,28.05,192504,DB02709,Resveratrol
,21907522,clearance,"Upon intravenous administration (0.75mg/kg), 2,4,3',4',5'-PMS displayed moderate clearance (58.5±19.5ml/min/kg) and terminal elimination half-life (147±61min).","Determination of trans-2,4,3',4',5'-pentamethoxystilbene in rat plasma and its application to a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21907522/),[ml] / [kg·min],58.5,193338,DB02709,Resveratrol
,21907522,terminal elimination half-life,"Upon intravenous administration (0.75mg/kg), 2,4,3',4',5'-PMS displayed moderate clearance (58.5±19.5ml/min/kg) and terminal elimination half-life (147±61min).","Determination of trans-2,4,3',4',5'-pentamethoxystilbene in rat plasma and its application to a pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21907522/),min,147,193339,DB02709,Resveratrol
,21907522,bioavailability,"When suspension was given (4mg/kg), the absolute oral bioavailability was almost nil; when 2,4,3',4',5'-PMS was fully solubilized by randomly methylated-β-cyclodextrin, it possessed a low bioavailability (3.63±2.06%).","Determination of trans-2,4,3',4',5'-pentamethoxystilbene in rat plasma and its application to a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21907522/),%,3.63,193340,DB02709,Resveratrol
,18004743,flow rate,"The plasma samples were extracted with ethyl acetate and analyzed using HPLC on an Aglient Zorbax SB-C(18) column (250 x 4.6 mm, 5 microm) at a wavelength 320 nm, with a linear gradient of (A) acetonitrile and (B) 0.5% aqueous acetic acid (v/v), at a flow rate of 1.0 mL/min.",High performance liquid chromatographic method for the determination and pharmacokinetic studies of oxyresveratrol and resveratrol in rat plasma after oral administration of Smilax china extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004743/),[ml] / [min],1.0,193587,DB02709,Resveratrol
,18004743,extraction recovery,"The extraction recovery for OXY, RES and internal standard ranged from 71.1 to 88.3%.",High performance liquid chromatographic method for the determination and pharmacokinetic studies of oxyresveratrol and resveratrol in rat plasma after oral administration of Smilax china extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004743/),%,71.1 to 88.3,193588,DB02709,Resveratrol
,33440781,absolute oral bioavailability (F%),"In rats, the absolute oral bioavailability (F%) of trans-resveratrol from Eudragit E/HCl solid dispersion (10/90) was estimated to be 40%.",Enhanced Oral Bioavailability of Resveratrol by Using Neutralized Eudragit E Solid Dispersion Prepared via Spray Drying. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33440781/),%,40,194206,DB02709,Resveratrol
,33176379,percentages of release,"The percentages of release for quercetin and resveratrol in the self-microemulsifying formulation were 75.88 ± 1.44 and 86.32 ± 2.32%, respectively, at 30 min.",Enhanced Oral Bioavailability and Improved Biological Activities of a Quercetin/Resveratrol Combination Using a Liquid Self-Microemulsifying Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176379/),%,75.88,194359,DB02709,Resveratrol
,33176379,percentages of release,"The percentages of release for quercetin and resveratrol in the self-microemulsifying formulation were 75.88 ± 1.44 and 86.32 ± 2.32%, respectively, at 30 min.",Enhanced Oral Bioavailability and Improved Biological Activities of a Quercetin/Resveratrol Combination Using a Liquid Self-Microemulsifying Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176379/),%,86.32,194360,DB02709,Resveratrol
,19035878,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of diltiazem in the presence of resveratrol (2.5 and 10 mg/kg) was significantly (P < 0.05) higher (10.2-11.1%) than that of the control (6.9%).","Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035878/),%,10.2-11.1,197861,DB02709,Resveratrol
,19035878,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of diltiazem in the presence of resveratrol (2.5 and 10 mg/kg) was significantly (P < 0.05) higher (10.2-11.1%) than that of the control (6.9%).","Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035878/),%,6.9,197862,DB02709,Resveratrol
,19488981,analytical recovery,The analytical recovery ranged from 95.5 +/- 3.7 to 103.2 +/- 0.7% while the absolute recovery ranged from 101.9 +/- 1.1 to 104.9 +/- 4.4%.,Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),%,95.5,197960,DB02709,Resveratrol
,19488981,analytical recovery,The analytical recovery ranged from 95.5 +/- 3.7 to 103.2 +/- 0.7% while the absolute recovery ranged from 101.9 +/- 1.1 to 104.9 +/- 4.4%.,Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),%,103.2,197961,DB02709,Resveratrol
,19488981,absolute recovery,The analytical recovery ranged from 95.5 +/- 3.7 to 103.2 +/- 0.7% while the absolute recovery ranged from 101.9 +/- 1.1 to 104.9 +/- 4.4%.,Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),%,101.9,197962,DB02709,Resveratrol
,19488981,absolute recovery,The analytical recovery ranged from 95.5 +/- 3.7 to 103.2 +/- 0.7% while the absolute recovery ranged from 101.9 +/- 1.1 to 104.9 +/- 4.4%.,Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),%,104.9,197963,DB02709,Resveratrol
,19488981,terminal elimination half-life,"The terminal elimination half-life and clearance of pterostilbene were 96.6 +/- 23.7 min and 37.0 +/- 2.5 mL/min/kg, respectively, while its absolute oral bioavailability was 12.5 +/- 4.7%.",Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),min,96.6,197964,DB02709,Resveratrol
,19488981,clearance,"The terminal elimination half-life and clearance of pterostilbene were 96.6 +/- 23.7 min and 37.0 +/- 2.5 mL/min/kg, respectively, while its absolute oral bioavailability was 12.5 +/- 4.7%.",Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),[ml] / [kg·min],37.0,197965,DB02709,Resveratrol
,19488981,absolute oral bioavailability,"The terminal elimination half-life and clearance of pterostilbene were 96.6 +/- 23.7 min and 37.0 +/- 2.5 mL/min/kg, respectively, while its absolute oral bioavailability was 12.5 +/- 4.7%.",Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488981/),%,12.5,197966,DB02709,Resveratrol
,33455290,vesicle size (VS),"The optimized liposomes formulation (RL5) was spherical with a vesicle size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03 ± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ± 8.04%.",Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455290/),nm,145.78,210807,DB02709,Resveratrol
,33455290,ζ potential (ZP),"The optimized liposomes formulation (RL5) was spherical with a vesicle size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03 ± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ± 8.04%.",Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455290/),mv,38.03,210808,DB02709,Resveratrol
,33455290,encapsulation efficiency (EE),"The optimized liposomes formulation (RL5) was spherical with a vesicle size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03 ± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ± 8.04%.",Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455290/),%,78.14,210809,DB02709,Resveratrol
,17294509,flow rate,"Mobile phase consisting of methanol and distilled water was used at a flow rate of 1.0 mL/min for the effective separation of cis-, trans-resveratrol and caffeine (IS).",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),[ml] / [min],1.0,216530,DB02709,Resveratrol
,17294509,Nominal retention times,"Nominal retention times of cis-, trans-resveratrol and IS were 3.2, 4.3 and 6.1 min, respectively.",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),min,3.2,216531,DB02709,Resveratrol
,17294509,Nominal retention times,"Nominal retention times of cis-, trans-resveratrol and IS were 3.2, 4.3 and 6.1 min, respectively.",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),min,4.3,216532,DB02709,Resveratrol
,17294509,Nominal retention times,"Nominal retention times of cis-, trans-resveratrol and IS were 3.2, 4.3 and 6.1 min, respectively.",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),min,6.1,216533,DB02709,Resveratrol
more,17294509,absolute recovery,The absolute recovery of both isomers was more than 85%.,Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),%,85,216534,DB02709,Resveratrol
,31609159,maximum drug loading,Formulation with maximum drug loading and entrapment efficiency of 8.4 ± 0.37% and 94.37 ± 1.01% respectively were further used for in vivo study.,Pharmacokinetics and brain targeting of trans-resveratrol loaded mixed micelles in rats following intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31609159/),%,8.4,218847,DB02709,Resveratrol
,31609159,entrapment efficiency,Formulation with maximum drug loading and entrapment efficiency of 8.4 ± 0.37% and 94.37 ± 1.01% respectively were further used for in vivo study.,Pharmacokinetics and brain targeting of trans-resveratrol loaded mixed micelles in rats following intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31609159/),%,94.37,218848,DB02709,Resveratrol
,31609159,AUC0-t,The AUC0-t for T-RES-MM was 460.98 ± 158.99 h*ng/ml while for T-RES it was 276.27 ± 174.05 h*ng/ml.,Pharmacokinetics and brain targeting of trans-resveratrol loaded mixed micelles in rats following intravenous administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31609159/),[h·ng] / [ml],460.98,218849,DB02709,Resveratrol
,31609159,AUC0-t,The AUC0-t for T-RES-MM was 460.98 ± 158.99 h*ng/ml while for T-RES it was 276.27 ± 174.05 h*ng/ml.,Pharmacokinetics and brain targeting of trans-resveratrol loaded mixed micelles in rats following intravenous administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31609159/),[h·ng] / [ml],276.27,218850,DB02709,Resveratrol
,25224342,solubility,Resveratrol has wide solubility ranging from 0.05 mg/mL in water to 374 mg/mL in polyethylene glycol 400 (PEG-400).,Pre-formulation studies of resveratrol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224342/),[mg] / [ml],0.05,219745,DB02709,Resveratrol
,25224342,solubility,Resveratrol has wide solubility ranging from 0.05 mg/mL in water to 374 mg/mL in polyethylene glycol 400 (PEG-400).,Pre-formulation studies of resveratrol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224342/),[mg] / [ml],374,219746,DB02709,Resveratrol
,25224342,PPB,The mean PPB of resveratrol is 98.3%.,Pre-formulation studies of resveratrol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224342/),,98,219747,DB02709,Resveratrol
,25224342,half lives,"Resveratrol degrades in human and rat plasma in a first-order process with mean half lives of 54 and 25 h, respectively.",Pre-formulation studies of resveratrol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224342/),h,54,219748,DB02709,Resveratrol
,25224342,half lives,"Resveratrol degrades in human and rat plasma in a first-order process with mean half lives of 54 and 25 h, respectively.",Pre-formulation studies of resveratrol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224342/),h,25,219749,DB02709,Resveratrol
,29292019,molar ratios,"In vivo study demonstrated that the molar ratios of RES-G/RES were 7.25±0.48 and 5.06±2.42 for free drug and SME-2, respectively, and the molar ratio decreased to 0.36±0.10 in SME-1 group.",Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29292019/),,7.25,220590,DB02709,Resveratrol
,29292019,molar ratios,"In vivo study demonstrated that the molar ratios of RES-G/RES were 7.25±0.48 and 5.06±2.42 for free drug and SME-2, respectively, and the molar ratio decreased to 0.36±0.10 in SME-1 group.",Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29292019/),,5.06,220591,DB02709,Resveratrol
,29292019,molar ratio,"In vivo study demonstrated that the molar ratios of RES-G/RES were 7.25±0.48 and 5.06±2.42 for free drug and SME-2, respectively, and the molar ratio decreased to 0.36±0.10 in SME-1 group.",Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29292019/),,0.36,220592,DB02709,Resveratrol
,29292019,bioavailability,Pharmacokinetic study confirmed that the inhibitory excipients containing SME demonstrated potential in increasing bioavailability of RES from 6.5% for the free RES and 12.9% for SME-2 to 76.1% in SME-1 through modulating the glucuronidation by UGT inhibitory excipients.,Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29292019/),%,6.5,220593,DB02709,Resveratrol
,29292019,bioavailability,Pharmacokinetic study confirmed that the inhibitory excipients containing SME demonstrated potential in increasing bioavailability of RES from 6.5% for the free RES and 12.9% for SME-2 to 76.1% in SME-1 through modulating the glucuronidation by UGT inhibitory excipients.,Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29292019/),%,12.9,220594,DB02709,Resveratrol
,29292019,bioavailability,Pharmacokinetic study confirmed that the inhibitory excipients containing SME demonstrated potential in increasing bioavailability of RES from 6.5% for the free RES and 12.9% for SME-2 to 76.1% in SME-1 through modulating the glucuronidation by UGT inhibitory excipients.,Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29292019/),%,76.1,220595,DB02709,Resveratrol
,18435437,Total recovery,Total recovery of the dietary administered piceid in urine ranged between 13.6 and 35.7%.,Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435437/),%,13.6 and 35.7,221870,DB02709,Resveratrol
<,23777612,half-life (t1/2,"Following intravenous administration (5 or 10mg/kg), plasma levels of pinosylvin declined rapidly with a short half-life (t1/2<10min).",Quantification of pinosylvin in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777612/),min,10,222191,DB02709,Resveratrol
<,23777612,oral bioavailability (F,"Upon oral administration at 15mg/kg, pinosylvin could not be quantified in plasma (<1ng/mL) while dose-escalation to 50mg/kg led to a low and erratic plasma exposure with very poor estimated oral bioavailability (F<1%).",Quantification of pinosylvin in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777612/),%,1,222192,DB02709,Resveratrol
,31571860,drug loading capacity,"BTM was successfully embedded in the core of PEG-PE micelles, with a drug loading capacity of 5.62±0.80%.","3,5,4'-trimethoxy-trans-stilbene loaded PEG-PE micelles for the treatment of colon cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571860/),%,5.62,223354,DB02709,Resveratrol
,33484925,AUCo-t,"In in vivo studies, resveratrol:Soluplus®: poloxamer 407 (1:2-15%) third generation solid dispersion presented an AUCo-t of 279 ± 54 ng.h/mL and a Cmax of 134 ± 78 ng/mL, 2.5 fold higher than solid dispersion without poloxamer 407.",Third-generation solid dispersion combining Soluplus and poloxamer 407 enhances the oral bioavailability of resveratrol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33484925/),[h·ng] / [ml],279,227241,DB02709,Resveratrol
,33484925,Cmax,"In in vivo studies, resveratrol:Soluplus®: poloxamer 407 (1:2-15%) third generation solid dispersion presented an AUCo-t of 279 ± 54 ng.h/mL and a Cmax of 134 ± 78 ng/mL, 2.5 fold higher than solid dispersion without poloxamer 407.",Third-generation solid dispersion combining Soluplus and poloxamer 407 enhances the oral bioavailability of resveratrol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33484925/),[ng] / [ml],134,227242,DB02709,Resveratrol
,19081693,flow rate,"Chromatographic separation was achieved on a RP-HPLC column (Agilent ZORBAX Eclipse Plus C18: 250 mm x 4.6mm i.d., 5microm), which was protected by a guard column (Agilent ZORBAX Eclipse Plus C18: 12.5 mm x 4.6mm i.d., 5microm) through isocratic delivery of a mobile phase of acetonitrile: water (75:25, v/v) at a flow rate of 1.2ml/min.","A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19081693/),[ml] / [min],1.2,228383,DB02709,Resveratrol
,19081693,retention time,"The retention time of TMS and trans-stilbene (internal standard) was 6.5 and 8.3min, respectively.","A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19081693/),min,6.5,228384,DB02709,Resveratrol
,19081693,retention time,"The retention time of TMS and trans-stilbene (internal standard) was 6.5 and 8.3min, respectively.","A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19081693/),min,8.3,228385,DB02709,Resveratrol
,19081693,absolute recovery,The mean absolute recovery of TMS in plasma ranged from 99.2 to 104.1%.,"A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19081693/),%,99.2 to 104.1,228386,DB02709,Resveratrol
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],6.771,228606,DB02709,Resveratrol
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],87.87,228607,DB02709,Resveratrol
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],45.11,228608,DB02709,Resveratrol
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],35.59,228609,DB02709,Resveratrol
,30218267,Tmax,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),h,2.00,228785,DB02709,Resveratrol
,30218267,Cmax,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),[μg] / [ml],3.66,228786,DB02709,Resveratrol
,30218267,AUC,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),[h·μg] / [ml],39.80,228787,DB02709,Resveratrol
,30218267,MRT,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),,20.49,228788,DB02709,Resveratrol
,30218267,Tmax,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),h,2.00,228789,DB02709,Resveratrol
,30218267,Cmax,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),[μg] / [ml],2.41,228790,DB02709,Resveratrol
,30218267,AUC,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),[h·μg] / [ml],12.82,228791,DB02709,Resveratrol
,30218267,MRT,"Results demonstrated that extrusion significantly increased the tamoxifen oral bioavailability (p < 0.05) (Tmax = 2.00 ± 0.56 h, Cmax = 3.66 ± 1.49 μg/mL, AUC = 39.80 ± 16.24 μg h/mL, MRT = 20.49 ± 5.71) compared to the conventional suspension of tamoxifen (Tmax = 2.00 ± 0.71 h, Cmax = 2.41 ± 0.84 μg/mL, AUC = 12.82 ± 3.99 μg h/mL, MRT = 18.24 ± 5.95 h).",Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218267/),h,18.24,228792,DB02709,Resveratrol
,31620434,IC50,Phosphonate modified MSNs significantly enhanced the anti-proliferative potential of RES with an IC50 of 7.15 μM as compared to 14.86 μM of free RES whereas amine modified MSNs didn't affect proliferation with an IC50 value higher than free RES (20.45 μM).,Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31620434/),μM,7.15,228806,DB02709,Resveratrol
,31620434,IC50,Phosphonate modified MSNs significantly enhanced the anti-proliferative potential of RES with an IC50 of 7.15 μM as compared to 14.86 μM of free RES whereas amine modified MSNs didn't affect proliferation with an IC50 value higher than free RES (20.45 μM).,Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31620434/),μM,14.86,228807,DB02709,Resveratrol
higher,31620434,IC50,Phosphonate modified MSNs significantly enhanced the anti-proliferative potential of RES with an IC50 of 7.15 μM as compared to 14.86 μM of free RES whereas amine modified MSNs didn't affect proliferation with an IC50 value higher than free RES (20.45 μM).,Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31620434/),μM,20.45,228808,DB02709,Resveratrol
,17500049,flow-rate,The flow-rate was 1.0 ml/min and ultraviolet detection was set at 320 nm.,Simultaneous determination of trans-resveratrol-3-O-glucoside and its two metabolites in rat plasma using liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17500049/),[ml] / [min],1.0,229172,DB02709,Resveratrol
,17500049,recoveries,"The mean recoveries of TRG, TRN, TR and I.S. were 93.6%, 93.1%, 91.0% and 87.9%, respectively.",Simultaneous determination of trans-resveratrol-3-O-glucoside and its two metabolites in rat plasma using liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17500049/),%,93.6,229173,DB02709,Resveratrol
,17500049,recoveries,"The mean recoveries of TRG, TRN, TR and I.S. were 93.6%, 93.1%, 91.0% and 87.9%, respectively.",Simultaneous determination of trans-resveratrol-3-O-glucoside and its two metabolites in rat plasma using liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17500049/),%,93.1,229174,DB02709,Resveratrol
,17500049,recoveries,"The mean recoveries of TRG, TRN, TR and I.S. were 93.6%, 93.1%, 91.0% and 87.9%, respectively.",Simultaneous determination of trans-resveratrol-3-O-glucoside and its two metabolites in rat plasma using liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17500049/),%,91.0,229175,DB02709,Resveratrol
,17500049,recoveries,"The mean recoveries of TRG, TRN, TR and I.S. were 93.6%, 93.1%, 91.0% and 87.9%, respectively.",Simultaneous determination of trans-resveratrol-3-O-glucoside and its two metabolites in rat plasma using liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17500049/),%,87.9,229176,DB02709,Resveratrol
,23326193,entrapment efficiency,An average resveratrol entrapment efficiency of ~70% was obtained for both SLNs and NLCs.,Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23326193/),%,70,232321,DB02709,Resveratrol
,23326193,polydispersity index,"Dynamic light scattering measurements gave a Z-average of 150-250 nm, polydispersity index of ~0.2, and a highly negative zeta potential of around -30 mV with no statistically significant differences in the presence of resveratrol.",Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23326193/),,0.2,232322,DB02709,Resveratrol
,32207071,zeta potential,"Unloaded and RSV-loaded NPs presented average diameter values in the range of 120-180 nm, narrow size distribution (polydispersity index < 0.150), and zeta potential of around + 20 mV.","Zein nanoparticles as low-cost, safe, and effective carriers to improve the oral bioavailability of resveratrol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32207071/),m,20,238239,DB02709,Resveratrol
,30156133,IC50,The IC50 of resveratrol was 8.745 µM in RLM and 7.789 µM in HLM.,Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156133/),μM,8.745,240282,DB02709,Resveratrol
,30156133,IC50,The IC50 of resveratrol was 8.745 µM in RLM and 7.789 µM in HLM.,Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156133/),μM,7.789,240283,DB02709,Resveratrol
,32868637,Cmax,"Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine.","A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868637/),[ng] / [ml],18.5,244009,DB02709,Resveratrol
,32868637,Cmax,"Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine.","A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868637/),,29,244010,DB02709,Resveratrol
,32868637,Cmax,"Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine.","A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868637/),,16,244011,DB02709,Resveratrol
,32868637,area under the concentration × time curve -,"Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine.","A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868637/),[ng] / [h·ml],1270,244012,DB02709,Resveratrol
,32868637,area under the concentration × time curve -,"Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine.","A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868637/),,2083,244013,DB02709,Resveratrol
,32868637,area under the concentration × time curve -,"Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine.","A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868637/),,1132,244014,DB02709,Resveratrol
,23417986,clearance (Cl,"Upon intravenous administration (2.5 mg/kg), PTS had rapid clearance (Cl = 68.2 ± 9.8 mL/min/kg) and moderate terminal elimination half-life (t(1/2λz) = 93.9 ± 22.3 min).","Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),[ml] / [kg·min],68.2,244192,DB02709,Resveratrol
,23417986,terminal elimination half-life (t(1/2λz),"Upon intravenous administration (2.5 mg/kg), PTS had rapid clearance (Cl = 68.2 ± 9.8 mL/min/kg) and moderate terminal elimination half-life (t(1/2λz) = 93.9 ± 22.3 min).","Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),min,93.9,244193,DB02709,Resveratrol
,23417986,Cl,Dose-escalation led to about twofold decline in clearance at the dose of 25 mg/kg (Cl = 36.4±7.8 mL/min/kg).,"Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),[ml] / [kg·min],36.4,244194,DB02709,Resveratrol
,23417986,bioavailability (F,"When given in oral suspension (15 mg/kg), PTS had relatively low bioavailability (F = 15.9 ± 7.8%) while fasting substantially attenuated its bioavailability (F< 5.5 %).","Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),%,15.9,244195,DB02709,Resveratrol
<,23417986,F,"When given in oral suspension (15 mg/kg), PTS had relatively low bioavailability (F = 15.9 ± 7.8%) while fasting substantially attenuated its bioavailability (F< 5.5 %).","Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),%,5.5,244196,DB02709,Resveratrol
,23417986,bioavailability (F,"However, when dosed in a solution formulated with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) (15 mg/kg), PTS possessed good bioavailability (F = 59.2 ± 19.6%).","Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),%,59.2,244197,DB02709,Resveratrol
,23417986,bioavailability (F,Sublingual delivery (2.5 mg/kg) led to rapid absorption and moderate bioavailability (F = 25.8 ± 13.1%).,"Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417986/),%,25.8,244198,DB02709,Resveratrol
,25799413,half life,But undergoes rapid metabolism in the body (half life 0.13h).,"Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25799413/),h,0.13,252335,DB02709,Resveratrol
,25799413,half-life,"Buffer and plasma stability of conjugates was dependent on polymer hydrophobicity, aggregation behavior and PEG corona, with MeO-PEG-PLAO-Succ-RSV (2 kDa) showing a 3h half-life in rat plasma in vitro.","Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25799413/),h,3,252336,DB02709,Resveratrol
,31415097,flow rate,The analyte and IS were separated on a C18 column by gradient elution with a mobile phase of acetonitrile-0.3% acetic acid at a flow rate of 0.25 mL/min for a total run time of 8 min.,Simultaneous ultra-performance liquid chromatography-tandem mass spectrometry determination of six components in rat plasma after oral administration of Smilacis glabrae Roxb. extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31415097/),[ml] / [min],0.25,256002,DB02709,Resveratrol
,31415097,total run time,The analyte and IS were separated on a C18 column by gradient elution with a mobile phase of acetonitrile-0.3% acetic acid at a flow rate of 0.25 mL/min for a total run time of 8 min.,Simultaneous ultra-performance liquid chromatography-tandem mass spectrometry determination of six components in rat plasma after oral administration of Smilacis glabrae Roxb. extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31415097/),min,8,256003,DB02709,Resveratrol
,33134392,flow rate,"The chromatographic separation of analytes and internal standard was performed on a Phenyl-Hexyl column (2.1 × 100 mm, 1.7 μm) with the mobile phase consisting of water (0.1% formic acid) and acetonitrile at a flow rate of 0.3 mL/min.",UPLC-MS/MS Method for the Simultaneous Quantification of Eight Compounds in Rat Plasma and Its Application to a Pharmacokinetic Study after Oral Administration of Veratrum (Veratrum nigrum L.) Extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134392/),[ml] / [min],0.3,259017,DB02709,Resveratrol
,33134392,extraction recoveries,"The extraction recoveries of the compounds were in the range of 85.1 ± 1.5% to 102.6 ± 8.0%, and the matrix effect ranged from 91.2 ± 4.5% to 113.8 ± 1.5%.",UPLC-MS/MS Method for the Simultaneous Quantification of Eight Compounds in Rat Plasma and Its Application to a Pharmacokinetic Study after Oral Administration of Veratrum (Veratrum nigrum L.) Extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134392/),%,85.1,259018,DB02709,Resveratrol
,33134392,extraction recoveries,"The extraction recoveries of the compounds were in the range of 85.1 ± 1.5% to 102.6 ± 8.0%, and the matrix effect ranged from 91.2 ± 4.5% to 113.8 ± 1.5%.",UPLC-MS/MS Method for the Simultaneous Quantification of Eight Compounds in Rat Plasma and Its Application to a Pharmacokinetic Study after Oral Administration of Veratrum (Veratrum nigrum L.) Extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134392/),%,102.6,259019,DB02709,Resveratrol
,33134392,matrix effect,"The extraction recoveries of the compounds were in the range of 85.1 ± 1.5% to 102.6 ± 8.0%, and the matrix effect ranged from 91.2 ± 4.5% to 113.8 ± 1.5%.",UPLC-MS/MS Method for the Simultaneous Quantification of Eight Compounds in Rat Plasma and Its Application to a Pharmacokinetic Study after Oral Administration of Veratrum (Veratrum nigrum L.) Extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134392/),%,91.2,259020,DB02709,Resveratrol
,33134392,matrix effect,"The extraction recoveries of the compounds were in the range of 85.1 ± 1.5% to 102.6 ± 8.0%, and the matrix effect ranged from 91.2 ± 4.5% to 113.8 ± 1.5%.",UPLC-MS/MS Method for the Simultaneous Quantification of Eight Compounds in Rat Plasma and Its Application to a Pharmacokinetic Study after Oral Administration of Veratrum (Veratrum nigrum L.) Extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134392/),%,113.8,259021,DB02709,Resveratrol
,33035579,en,Obtained results demonstrated that the prepared formulations encapsulated the resveratrol with high encapsulation efficiency of 90.7% ± 5.1% for PLGA-RSV and 59.1% ± 3.3% for PLGA-FA-RSV.,Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035579/),%,90.7,259521,DB02709,Resveratrol
,33035579,en,Obtained results demonstrated that the prepared formulations encapsulated the resveratrol with high encapsulation efficiency of 90.7% ± 5.1% for PLGA-RSV and 59.1% ± 3.3% for PLGA-FA-RSV.,Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035579/),%,59.1,259522,DB02709,Resveratrol
,33035579,trans-well permeability rates,"The trans-well permeability rates through Caco-2 monolayer during 180 min, was determined to be 4.5%, 61% and 99% for resveratrol, PLGA-RSV and PLGA-FA-RSV respectively.",Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035579/),%,4.5,259523,DB02709,Resveratrol
,33035579,trans-well permeability rates,"The trans-well permeability rates through Caco-2 monolayer during 180 min, was determined to be 4.5%, 61% and 99% for resveratrol, PLGA-RSV and PLGA-FA-RSV respectively.",Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035579/),%,61,259524,DB02709,Resveratrol
,33035579,trans-well permeability rates,"The trans-well permeability rates through Caco-2 monolayer during 180 min, was determined to be 4.5%, 61% and 99% for resveratrol, PLGA-RSV and PLGA-FA-RSV respectively.",Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035579/),%,99,259525,DB02709,Resveratrol
,32322856,maximum value,"The cellular uptake of encapsulated resveratrol increased appreciably with observation time (1-4 h), reaching a maximum value (≈1.06 μg mL-1) after 2 h, whereas that of free resveratrol (in DMSO) only increased slightly, reaching 0.62 μg mL-1 after 4 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],1.06,259735,DB02709,Resveratrol
,32322856,maximum value,"The cellular uptake of encapsulated resveratrol increased appreciably with observation time (1-4 h), reaching a maximum value (≈1.06 μg mL-1) after 2 h, whereas that of free resveratrol (in DMSO) only increased slightly, reaching 0.62 μg mL-1 after 4 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],0.62,259736,DB02709,Resveratrol
,32322856,maximum,"The plasma level reached a maximum value of 1.35 ± 0.26 μg mL-1 at 4 h after feeding the En-RES formulation, and then decreased to 0.19 ± 0.04 μg mL-1 after 48 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],1.35,259737,DB02709,Resveratrol
,32322856,maximum,"Conversely, the plasma level only reached a maximum value of 0.31 ± 0.05 μg mL-1 at 0.5 h after feeding the free resveratrol formulation (an aqueous PEG 400 solution), and was totally cleared after 8 h.",Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322856/),[μg] / [ml],0.31,259738,DB02709,Resveratrol
,24561334,retention times,Resv and Resv metabolites were analyzed in the negative electrospray ionization mode and eluted with retention times of about 0.69-2.22min with a runtime of 7min.,Simultaneous quantification of trans-resveratrol and its sulfate and glucuronide metabolites in rat tissues by stable isotope-dilution UPLC-MS/MS analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561334/),min,0.69-2.22,261282,DB02709,Resveratrol
,24561334,runtime,Resv and Resv metabolites were analyzed in the negative electrospray ionization mode and eluted with retention times of about 0.69-2.22min with a runtime of 7min.,Simultaneous quantification of trans-resveratrol and its sulfate and glucuronide metabolites in rat tissues by stable isotope-dilution UPLC-MS/MS analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561334/),min,7,261283,DB02709,Resveratrol
,26657178,flow rate,"Analytes were separated using a Sepax BR-C18 analytical column (5μm, 120Å, 1.0×100mm) and eluted using an isocratic elution mobile phase acetonitrile and 0.01% formic acid [60:40, v/v] at a flow rate of 0.1mL/min.",Validated LC-MS/MS method for simultaneous quantification of resveratrol levels in mouse plasma and brain and its application to pharmacokinetic and brain distribution studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26657178/),[ml] / [min],0.1,264132,DB02709,Resveratrol
,21361135,polydispersity index,"The lipid-core nanocapsules had a mean diameter of 241 nm, a polydispersity index of 0.2, and a zeta potential of -15 mV.",Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361135/),,0.2,264646,DB02709,Resveratrol
,24495149,tmax,"Plasma tRV concentrations with enzymatic hydrolysis were maintained over 24 h, with a tmax of 12 h and a mean residence time (MRT) of 14 h, 5 and 2 times higher than those for tRV powder intake, respectively.",Pharmacokinetics and safety of resveratrol derivatives in humans after oral administration of melinjo (Gnetum gnemon L.) seed extract powder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24495149/),h,12,265494,DB02709,Resveratrol
,24495149,mean residence time (MRT),"Plasma tRV concentrations with enzymatic hydrolysis were maintained over 24 h, with a tmax of 12 h and a mean residence time (MRT) of 14 h, 5 and 2 times higher than those for tRV powder intake, respectively.",Pharmacokinetics and safety of resveratrol derivatives in humans after oral administration of melinjo (Gnetum gnemon L.) seed extract powder. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24495149/),h,14,265495,DB02709,Resveratrol
,23146234,clearance (Cl,DFS displayed moderate clearance (Cl=61.5 ± 17.7 ml/min/kg) and a relatively prolonged terminal elimination half-life (t(1/2 λz)) of 351 ± 180 min.,"Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146234/),[ml] / [kg·min],61.5,265950,DB02709,Resveratrol
,23146234,terminal elimination half-life (t(1/2 λz)),DFS displayed moderate clearance (Cl=61.5 ± 17.7 ml/min/kg) and a relatively prolonged terminal elimination half-life (t(1/2 λz)) of 351 ± 180 min.,"Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146234/),min,351,265951,DB02709,Resveratrol
,23146234,F,"However, when DFS was given in a solution prepared with hydroxypropyl-β-cyclodextrin (6 mg/kg), the F was 12.4 ± 10.7%.","Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146234/),%,12.4,265952,DB02709,Resveratrol
,23146234,F,Dose-escalation to 15 mg/kg resulted in much higher systemic exposure (F=40.2 ± 10.0%).,"Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146234/),%,40.2,265953,DB02709,Resveratrol
,29578462,AUC0∼t,The in vivo pharmacokinetic test in rats showed that the AUC0∼t of t-Res NS (559.4 μg/mL·min) was about 3.6-fold higher than that of t-Res solution.,Preparation and in vitro-in vivo characterization of trans-resveratrol nanosuspensions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29578462/),[μg] / [min·ml],559.4,268796,DB02709,Resveratrol
